0000724004 MESA LABORATORIES INC /CO false --03-31 Q2 2022 238 218 0 0 250,000,000 250,000,000 5,223,232 5,223,232 5,140,568 5,140,568 0.16 0.16 9,315 0.16 0.16 4 22,799 0 0 4 6 1.375 1.375 1.375 1.375 1 1 225.00 2018 2019 3 Non-reportable operating segments and unallocated corporate expenses are reported within Corporate and Other. Balances for performance-based restricted stock units ("PSUs") are reflected at target. During the three months ended June 30, 2021, the fiscal year 2019 PSUs vested and were paid at 280% of target, based on actual performance results and completion of service conditions. In addition, the PSUs granted to employees of Gyros Protein Technologies Holding AB vested at 60% of target, following a modification of the performance targets by the Compensation Committee of the Board of Directors during fiscal year 2021. Accumulated Other Comprehensive Income (Loss). Intersegment revenues are not significant and are eliminated to arrive at consolidated totals. 0000724004 2021-04-01 2021-09-30 xbrli:shares 0000724004 2021-10-29 thunderdome:item iso4217:USD 0000724004 2021-09-30 0000724004 2021-03-31 iso4217:USD xbrli:shares 0000724004 us-gaap:ProductMember 2021-07-01 2021-09-30 0000724004 us-gaap:ProductMember 2020-07-01 2020-09-30 0000724004 us-gaap:ProductMember 2021-04-01 2021-09-30 0000724004 us-gaap:ProductMember 2020-04-01 2020-09-30 0000724004 2021-07-01 2021-09-30 0000724004 2020-07-01 2020-09-30 0000724004 2020-04-01 2020-09-30 0000724004 2020-03-31 0000724004 2020-09-30 0000724004 us-gaap:CommonStockMember 2021-03-31 0000724004 us-gaap:RetainedEarningsMember 2021-03-31 0000724004 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000724004 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0000724004 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000724004 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0000724004 2021-04-01 2021-06-30 0000724004 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:CommonStockMember 2021-03-31 0000724004 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2021-03-31 0000724004 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000724004 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2021-03-31 0000724004 us-gaap:CommonStockMember 2021-06-30 0000724004 us-gaap:RetainedEarningsMember 2021-06-30 0000724004 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000724004 2021-06-30 0000724004 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000724004 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000724004 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0000724004 us-gaap:CommonStockMember 2021-09-30 0000724004 us-gaap:RetainedEarningsMember 2021-09-30 0000724004 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0000724004 us-gaap:CommonStockMember 2020-03-31 0000724004 us-gaap:RetainedEarningsMember 2020-03-31 0000724004 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000724004 2020-04-01 2020-06-30 0000724004 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0000724004 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000724004 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0000724004 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:CommonStockMember 2020-03-31 0000724004 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2020-03-31 0000724004 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000724004 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2020-03-31 0000724004 us-gaap:CommonStockMember 2020-06-30 0000724004 us-gaap:RetainedEarningsMember 2020-06-30 0000724004 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000724004 2020-06-30 0000724004 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000724004 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000724004 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000724004 us-gaap:CommonStockMember 2020-09-30 0000724004 us-gaap:RetainedEarningsMember 2020-09-30 0000724004 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 xbrli:pure 0000724004 us-gaap:AccountingStandardsUpdate202006Member 2021-04-01 0000724004 us-gaap:OperatingSegmentsMember mlab:ConsumablesMember mlab:SterilizationAndDisinfectionControlMember us-gaap:TransferredAtPointInTimeMember 2021-07-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ConsumablesMember mlab:BiopharmaceuticalDevelopmentMember us-gaap:TransferredAtPointInTimeMember 2021-07-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ConsumablesMember mlab:InstrumentsMember us-gaap:TransferredAtPointInTimeMember 2021-07-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ConsumablesMember mlab:ContinuousMonitoringMember us-gaap:TransferredAtPointInTimeMember 2021-07-01 2021-09-30 0000724004 mlab:ConsumablesMember us-gaap:TransferredAtPointInTimeMember 2021-07-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:HardwareAndSoftwareMember mlab:SterilizationAndDisinfectionControlMember us-gaap:TransferredAtPointInTimeMember 2021-07-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:HardwareAndSoftwareMember mlab:BiopharmaceuticalDevelopmentMember us-gaap:TransferredAtPointInTimeMember 2021-07-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:HardwareAndSoftwareMember mlab:InstrumentsMember us-gaap:TransferredAtPointInTimeMember 2021-07-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:HardwareAndSoftwareMember mlab:ContinuousMonitoringMember us-gaap:TransferredAtPointInTimeMember 2021-07-01 2021-09-30 0000724004 mlab:HardwareAndSoftwareMember us-gaap:TransferredAtPointInTimeMember 2021-07-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember mlab:SterilizationAndDisinfectionControlMember us-gaap:TransferredAtPointInTimeMember 2021-07-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember mlab:BiopharmaceuticalDevelopmentMember us-gaap:TransferredAtPointInTimeMember 2021-07-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember mlab:InstrumentsMember us-gaap:TransferredAtPointInTimeMember 2021-07-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember mlab:ContinuousMonitoringMember us-gaap:TransferredAtPointInTimeMember 2021-07-01 2021-09-30 0000724004 us-gaap:ServiceMember us-gaap:TransferredAtPointInTimeMember 2021-07-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ServicesAndSoftwareMember mlab:SterilizationAndDisinfectionControlMember us-gaap:TransferredOverTimeMember 2021-07-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ServicesAndSoftwareMember mlab:BiopharmaceuticalDevelopmentMember us-gaap:TransferredOverTimeMember 2021-07-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ServicesAndSoftwareMember mlab:InstrumentsMember us-gaap:TransferredOverTimeMember 2021-07-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ServicesAndSoftwareMember mlab:ContinuousMonitoringMember us-gaap:TransferredOverTimeMember 2021-07-01 2021-09-30 0000724004 mlab:ServicesAndSoftwareMember us-gaap:TransferredOverTimeMember 2021-07-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:SterilizationAndDisinfectionControlMember 2021-07-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:BiopharmaceuticalDevelopmentMember 2021-07-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:InstrumentsMember 2021-07-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ContinuousMonitoringMember 2021-07-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ConsumablesMember mlab:SterilizationAndDisinfectionControlMember us-gaap:TransferredAtPointInTimeMember 2020-07-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ConsumablesMember mlab:BiopharmaceuticalDevelopmentMember us-gaap:TransferredAtPointInTimeMember 2020-07-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ConsumablesMember mlab:InstrumentsMember us-gaap:TransferredAtPointInTimeMember 2020-07-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ConsumablesMember mlab:ContinuousMonitoringMember us-gaap:TransferredAtPointInTimeMember 2020-07-01 2020-09-30 0000724004 mlab:ConsumablesMember us-gaap:TransferredAtPointInTimeMember 2020-07-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:HardwareAndSoftwareMember mlab:SterilizationAndDisinfectionControlMember us-gaap:TransferredAtPointInTimeMember 2020-07-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:HardwareAndSoftwareMember mlab:BiopharmaceuticalDevelopmentMember us-gaap:TransferredAtPointInTimeMember 2020-07-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:HardwareAndSoftwareMember mlab:InstrumentsMember us-gaap:TransferredAtPointInTimeMember 2020-07-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:HardwareAndSoftwareMember mlab:ContinuousMonitoringMember us-gaap:TransferredAtPointInTimeMember 2020-07-01 2020-09-30 0000724004 mlab:HardwareAndSoftwareMember us-gaap:TransferredAtPointInTimeMember 2020-07-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember mlab:SterilizationAndDisinfectionControlMember us-gaap:TransferredAtPointInTimeMember 2020-07-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember mlab:BiopharmaceuticalDevelopmentMember us-gaap:TransferredAtPointInTimeMember 2020-07-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember mlab:InstrumentsMember us-gaap:TransferredAtPointInTimeMember 2020-07-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember mlab:ContinuousMonitoringMember us-gaap:TransferredAtPointInTimeMember 2020-07-01 2020-09-30 0000724004 us-gaap:ServiceMember us-gaap:TransferredAtPointInTimeMember 2020-07-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ServicesAndSoftwareMember mlab:SterilizationAndDisinfectionControlMember us-gaap:TransferredOverTimeMember 2020-07-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ServicesAndSoftwareMember mlab:BiopharmaceuticalDevelopmentMember us-gaap:TransferredOverTimeMember 2020-07-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ServicesAndSoftwareMember mlab:InstrumentsMember us-gaap:TransferredOverTimeMember 2020-07-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ServicesAndSoftwareMember mlab:ContinuousMonitoringMember us-gaap:TransferredOverTimeMember 2020-07-01 2020-09-30 0000724004 mlab:ServicesAndSoftwareMember us-gaap:TransferredOverTimeMember 2020-07-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:SterilizationAndDisinfectionControlMember 2020-07-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:BiopharmaceuticalDevelopmentMember 2020-07-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:InstrumentsMember 2020-07-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ContinuousMonitoringMember 2020-07-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ConsumablesMember mlab:SterilizationAndDisinfectionControlMember us-gaap:TransferredAtPointInTimeMember 2021-04-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ConsumablesMember mlab:BiopharmaceuticalDevelopmentMember us-gaap:TransferredAtPointInTimeMember 2021-04-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ConsumablesMember mlab:InstrumentsMember us-gaap:TransferredAtPointInTimeMember 2021-04-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ConsumablesMember mlab:ContinuousMonitoringMember us-gaap:TransferredAtPointInTimeMember 2021-04-01 2021-09-30 0000724004 mlab:ConsumablesMember us-gaap:TransferredAtPointInTimeMember 2021-04-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:HardwareAndSoftwareMember mlab:SterilizationAndDisinfectionControlMember us-gaap:TransferredAtPointInTimeMember 2021-04-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:HardwareAndSoftwareMember mlab:BiopharmaceuticalDevelopmentMember us-gaap:TransferredAtPointInTimeMember 2021-04-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:HardwareAndSoftwareMember mlab:InstrumentsMember us-gaap:TransferredAtPointInTimeMember 2021-04-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:HardwareAndSoftwareMember mlab:ContinuousMonitoringMember us-gaap:TransferredAtPointInTimeMember 2021-04-01 2021-09-30 0000724004 mlab:HardwareAndSoftwareMember us-gaap:TransferredAtPointInTimeMember 2021-04-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember mlab:SterilizationAndDisinfectionControlMember us-gaap:TransferredAtPointInTimeMember 2021-04-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember mlab:BiopharmaceuticalDevelopmentMember us-gaap:TransferredAtPointInTimeMember 2021-04-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember mlab:InstrumentsMember us-gaap:TransferredAtPointInTimeMember 2021-04-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember mlab:ContinuousMonitoringMember us-gaap:TransferredAtPointInTimeMember 2021-04-01 2021-09-30 0000724004 us-gaap:ServiceMember us-gaap:TransferredAtPointInTimeMember 2021-04-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ServicesAndSoftwareMember mlab:SterilizationAndDisinfectionControlMember us-gaap:TransferredOverTimeMember 2021-04-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ServicesAndSoftwareMember mlab:BiopharmaceuticalDevelopmentMember us-gaap:TransferredOverTimeMember 2021-04-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ServicesAndSoftwareMember mlab:InstrumentsMember us-gaap:TransferredOverTimeMember 2021-04-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ServicesAndSoftwareMember mlab:ContinuousMonitoringMember us-gaap:TransferredOverTimeMember 2021-04-01 2021-09-30 0000724004 mlab:ServicesAndSoftwareMember us-gaap:TransferredOverTimeMember 2021-04-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:SterilizationAndDisinfectionControlMember 2021-04-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:BiopharmaceuticalDevelopmentMember 2021-04-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:InstrumentsMember 2021-04-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ContinuousMonitoringMember 2021-04-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ConsumablesMember mlab:SterilizationAndDisinfectionControlMember us-gaap:TransferredAtPointInTimeMember 2020-04-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ConsumablesMember mlab:BiopharmaceuticalDevelopmentMember us-gaap:TransferredAtPointInTimeMember 2020-04-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ConsumablesMember mlab:InstrumentsMember us-gaap:TransferredAtPointInTimeMember 2020-04-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ConsumablesMember mlab:ContinuousMonitoringMember us-gaap:TransferredAtPointInTimeMember 2020-04-01 2020-09-30 0000724004 mlab:ConsumablesMember us-gaap:TransferredAtPointInTimeMember 2020-04-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:HardwareAndSoftwareMember mlab:SterilizationAndDisinfectionControlMember us-gaap:TransferredAtPointInTimeMember 2020-04-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:HardwareAndSoftwareMember mlab:BiopharmaceuticalDevelopmentMember us-gaap:TransferredAtPointInTimeMember 2020-04-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:HardwareAndSoftwareMember mlab:InstrumentsMember us-gaap:TransferredAtPointInTimeMember 2020-04-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:HardwareAndSoftwareMember mlab:ContinuousMonitoringMember us-gaap:TransferredAtPointInTimeMember 2020-04-01 2020-09-30 0000724004 mlab:HardwareAndSoftwareMember us-gaap:TransferredAtPointInTimeMember 2020-04-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember mlab:SterilizationAndDisinfectionControlMember us-gaap:TransferredAtPointInTimeMember 2020-04-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember mlab:BiopharmaceuticalDevelopmentMember us-gaap:TransferredAtPointInTimeMember 2020-04-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember mlab:InstrumentsMember us-gaap:TransferredAtPointInTimeMember 2020-04-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember mlab:ContinuousMonitoringMember us-gaap:TransferredAtPointInTimeMember 2020-04-01 2020-09-30 0000724004 us-gaap:ServiceMember us-gaap:TransferredAtPointInTimeMember 2020-04-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ServicesAndSoftwareMember mlab:SterilizationAndDisinfectionControlMember us-gaap:TransferredOverTimeMember 2020-04-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ServicesAndSoftwareMember mlab:BiopharmaceuticalDevelopmentMember us-gaap:TransferredOverTimeMember 2020-04-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ServicesAndSoftwareMember mlab:InstrumentsMember us-gaap:TransferredOverTimeMember 2020-04-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ServicesAndSoftwareMember mlab:ContinuousMonitoringMember us-gaap:TransferredOverTimeMember 2020-04-01 2020-09-30 0000724004 mlab:ServicesAndSoftwareMember us-gaap:TransferredOverTimeMember 2020-04-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:SterilizationAndDisinfectionControlMember 2020-04-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:BiopharmaceuticalDevelopmentMember 2020-04-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:InstrumentsMember 2020-04-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ContinuousMonitoringMember 2020-04-01 2020-09-30 0000724004 country:US 2021-07-01 2021-09-30 0000724004 country:US 2020-07-01 2020-09-30 0000724004 country:US 2021-04-01 2021-09-30 0000724004 country:US 2020-04-01 2020-09-30 0000724004 us-gaap:NonUsMember 2021-07-01 2021-09-30 0000724004 us-gaap:NonUsMember 2020-07-01 2020-09-30 0000724004 us-gaap:NonUsMember 2021-04-01 2021-09-30 0000724004 us-gaap:NonUsMember 2020-04-01 2020-09-30 0000724004 mlab:TheNotesMember us-gaap:SeniorNotesMember 2021-03-31 0000724004 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SeniorNotesMember 2021-09-30 0000724004 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember 2021-09-30 0000724004 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SeniorNotesMember 2021-03-31 0000724004 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember 2021-03-31 0000724004 us-gaap:IntellectualPropertyMember 2021-09-30 0000724004 us-gaap:IntellectualPropertyMember 2021-03-31 0000724004 us-gaap:TradeNamesMember 2021-09-30 0000724004 us-gaap:TradeNamesMember 2021-03-31 0000724004 us-gaap:CustomerRelationshipsMember 2021-09-30 0000724004 us-gaap:CustomerRelationshipsMember 2021-03-31 0000724004 us-gaap:NoncompeteAgreementsMember 2021-09-30 0000724004 us-gaap:NoncompeteAgreementsMember 2021-03-31 0000724004 us-gaap:OperatingSegmentsMember mlab:SterilizationAndDisinfectionControlMember 2021-03-31 0000724004 us-gaap:OperatingSegmentsMember mlab:BiopharmaceuticalDevelopmentMember 2021-03-31 0000724004 us-gaap:OperatingSegmentsMember mlab:InstrumentsMember 2021-03-31 0000724004 us-gaap:OperatingSegmentsMember mlab:ContinuousMonitoringMember 2021-03-31 0000724004 us-gaap:OperatingSegmentsMember mlab:SterilizationAndDisinfectionControlMember 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:BiopharmaceuticalDevelopmentMember 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:InstrumentsMember 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember mlab:ContinuousMonitoringMember 2021-09-30 utr:Y 0000724004 mlab:SeniorSecuredCreditAgreementMember 2021-03-05 2021-03-05 0000724004 us-gaap:RevolvingCreditFacilityMember mlab:SeniorSecuredCreditAgreementMember 2021-03-05 0000724004 mlab:SeniorSecuredCreditAgreementMember srt:MaximumMember mlab:SwinglineLoanMember 2021-03-05 0000724004 us-gaap:LetterOfCreditMember mlab:SeniorSecuredCreditAgreementMember srt:MaximumMember 2021-03-05 0000724004 mlab:SeniorSecuredCreditAgreementMember mlab:TheCreditFacilityTermLoanMember srt:MinimumMember 2021-03-05 0000724004 mlab:SeniorSecuredCreditAgreementMember mlab:TheCreditFacilityTermLoanMember srt:MaximumMember 2021-03-05 0000724004 mlab:PrepaidExpensesOtherAndOtherAssetsMember mlab:SeniorSecuredCreditAgreementMember 2021-09-30 0000724004 mlab:PrepaidExpensesOtherAndOtherAssetsMember mlab:SeniorSecuredCreditAgreementMember 2021-03-31 0000724004 mlab:SeniorSecuredCreditAgreementMember srt:MinimumMember 2021-03-05 2021-03-05 0000724004 mlab:SeniorSecuredCreditAgreementMember 2021-09-30 0000724004 mlab:SeniorSecuredCreditAgreementMember us-gaap:SubsequentEventMember 2021-10-18 2021-10-18 0000724004 mlab:SeniorSecuredCreditAgreementMember srt:MaximumMember 2021-03-05 2021-03-05 0000724004 mlab:SeniorSecuredCreditAgreementMember 2021-03-06 2021-09-30 0000724004 mlab:SeniorSecuredCreditAgreementMember 2021-07-01 2021-09-30 0000724004 mlab:SeniorSecuredCreditAgreementMember 2021-04-01 2021-09-30 0000724004 mlab:SeniorSecuredCreditAgreementMember 2020-07-01 2020-09-30 0000724004 mlab:SeniorSecuredCreditAgreementMember 2020-04-01 2020-09-30 0000724004 mlab:TheNotesMember us-gaap:SeniorNotesMember 2019-08-12 0000724004 mlab:TheNotesMember us-gaap:SeniorNotesMember 2019-08-12 2019-08-12 0000724004 mlab:TheNotesMember us-gaap:SeniorNotesMember 2021-09-30 0000724004 mlab:TheNotesMember 2021-09-30 0000724004 mlab:TheNotesMember 2020-09-30 0000724004 mlab:TheNotesMember 2021-07-01 2021-09-30 0000724004 mlab:TheNotesMember 2020-07-01 2020-09-30 0000724004 mlab:TheNotesMember 2021-04-01 2021-09-30 0000724004 mlab:TheNotesMember 2020-04-01 2020-09-30 0000724004 mlab:TheNotesMember us-gaap:SeniorNotesMember 2021-04-30 0000724004 mlab:The2021EquityPlanMember 2021-09-30 0000724004 2020-04-01 2021-03-31 0000724004 us-gaap:RestrictedStockUnitsRSUMember 2021-03-31 0000724004 mlab:PerformanceStockUnitsMember 2021-03-31 0000724004 us-gaap:RestrictedStockUnitsRSUMember 2021-04-01 2021-09-30 0000724004 mlab:PerformanceStockUnitsMember 2021-04-01 2021-09-30 0000724004 us-gaap:RestrictedStockUnitsRSUMember 2021-09-30 0000724004 mlab:PerformanceStockUnitsMember 2021-09-30 0000724004 mlab:TheFY19PSUsMember 2021-04-01 2021-09-30 0000724004 mlab:GPTPSUsMember 2021-04-01 2021-09-30 0000724004 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2021-04-01 2021-09-30 0000724004 mlab:TheFY20PSUsMember 2019-04-01 2020-03-31 0000724004 mlab:TheFY20PSUsMember srt:MinimumMember 2021-04-01 2021-09-30 0000724004 mlab:TheFY20PSUsMember srt:MaximumMember 2021-04-01 2021-09-30 0000724004 mlab:TheFY20PSUsMember 2021-07-01 2021-09-30 0000724004 us-gaap:RestrictedStockUnitsRSUMember srt:ChiefExecutiveOfficerMember 2021-04-01 2021-06-30 0000724004 us-gaap:RestrictedStockUnitsRSUMember srt:ChiefExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-04-01 2021-06-30 0000724004 mlab:PublicOfferingMember 2020-06-12 2020-06-12 0000724004 us-gaap:OverAllotmentOptionMember 2020-06-19 2020-06-19 0000724004 mlab:PublicOfferingMember 2020-06-19 0000724004 mlab:PublicOfferingMember 2020-06-12 0000724004 mlab:PublicOfferingMember 2020-06-12 2020-06-19 0000724004 mlab:AssumedConversionOfConvertibleDebtMember 2021-07-01 2021-09-30 0000724004 mlab:AssumedConversionOfConvertibleDebtMember 2020-07-01 2020-09-30 0000724004 mlab:AssumedConversionOfConvertibleDebtMember 2021-04-01 2021-09-30 0000724004 mlab:AssumedConversionOfConvertibleDebtMember 2020-04-01 2020-09-30 0000724004 mlab:StockAwardsThatWereAntidilutiveMember 2021-07-01 2021-09-30 0000724004 mlab:StockAwardsThatWereAntidilutiveMember 2020-07-01 2020-09-30 0000724004 mlab:StockAwardsThatWereAntidilutiveMember 2021-04-01 2021-09-30 0000724004 mlab:StockAwardsThatWereAntidilutiveMember 2020-04-01 2020-09-30 0000724004 mlab:StockAwardsSubjectToPerformanceConditionsMember 2021-07-01 2021-09-30 0000724004 mlab:StockAwardsSubjectToPerformanceConditionsMember 2020-07-01 2020-09-30 0000724004 mlab:StockAwardsSubjectToPerformanceConditionsMember 2021-04-01 2021-09-30 0000724004 mlab:StockAwardsSubjectToPerformanceConditionsMember 2020-04-01 2020-09-30 0000724004 mlab:GyrosUSIncMember 2021-04-01 2021-09-30 0000724004 mlab:LiabilityForCollectingAndRemittingSalesTaxStatesWithEstablishedNexusMember 2021-09-30 0000724004 mlab:LiabilityForCollectingAndRemittingSalesTaxStatesWithEstablishedNexusMember 2021-03-31 0000724004 mlab:GPTAcquisitionMember 2021-04-01 2021-09-30 0000724004 mlab:AgenaMember us-gaap:SubsequentEventMember 2021-10-20 2021-10-20 0000724004 mlab:ClosureOfOurButlerNewJerseyFacilityMember 2021-04-01 2021-09-30 0000724004 mlab:ClosureOfOurButlerNewJerseyFacilityMember 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember 2021-07-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember 2020-07-01 2020-09-30 0000724004 us-gaap:OperatingSegmentsMember 2021-04-01 2021-09-30 0000724004 us-gaap:OperatingSegmentsMember 2020-04-01 2020-09-30 0000724004 us-gaap:CorporateNonSegmentMember 2021-07-01 2021-09-30 0000724004 us-gaap:CorporateNonSegmentMember 2020-07-01 2020-09-30 0000724004 us-gaap:CorporateNonSegmentMember 2021-04-01 2021-09-30 0000724004 us-gaap:CorporateNonSegmentMember 2020-04-01 2020-09-30 0000724004 mlab:PerformanceStockUnitsMember us-gaap:SubsequentEventMember srt:ChiefExecutiveOfficerMember 2021-10-28 2021-10-28

Table of Contents

United States

Securities and Exchange Commission

Washington, D.C. 20549

FORM 10-Q

| ☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2021

or

| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___ to ___

Commission File No: 0-11740

MESA LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

| Colorado |  | 84-0872291 |
| (State or other jurisdiction of |  | (I.R.S. Employer |
| incorporation or organization) |  | Identification number) |
| 12100 West Sixth Avenue |  |  |
| Lakewood, Colorado |  | 80228 |
| (Address of principal executive offices) |  | (Zip Code) |

Registrant’s telephone number, including area code: (303) 987-8000

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol | Name on each exchange on which registered
Common Stock, no par value | MLAB | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934, during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒ | Accelerated filer ☐ | Non-accelerated filer ☐ | Smaller reporting company ☐ | Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

Indicate the number of shares outstanding of each of the Issuer’s classes of common stock, as of the latest practicable date:

There were 5,225,232 shares of the Issuer’s common stock, no par value, outstanding as of October 29, 2021.

Table of Contents

Table of Contents

Part I. Financial Information | 1
| Item 1. Financial Statements | 1
| Condensed Consolidated Balance Sheets | 1
| Condensed Consolidated Statements of Income | 2
| Condensed Consolidated Statements of Comprehensive (Loss) Income | 3
| Condensed Consolidated Statements of Cash Flows | 4
| Condensed Consolidated Statements of Stockholders’ Equity | 5
| Notes to Condensed Consolidated Financial Statements | 6
| Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations | 16
| Item 3. Quantitative and Qualitative Disclosures about Market Risk | 23
| Item 4. Controls and Procedures | 23
Part II. Other Information | 24
| Item 1. Legal Proceedings | 24
| Item 1A. Risk factors | 24
| Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | 24
| Item 6. Exhibits | 25
| Signatures | 26
| Exhibit 31.1 Certifications Pursuant to Rule 13a-14(a) |
| Exhibit 31.2 Certifications Pursuant to Rule 13a-14(a) |
| Exhibit 32.1 Certifications Pursuant to Rule 13a-14(b) and 18 U.S.C Section 1350 |
| Exhibit 32.2 Certifications Pursuant to Rule 13a-14(b) and 18 U.S.C Section 1350 |

Table of Contents

Part I. Financial Information

Item 1. Financial Statements

Mesa Laboratories, Inc.

Condensed Consolidated Balance Sheets

(unaudited)

(dollars in thousands, except share amounts)

|  | September 30, |  |  | March 31, |
|  | 2021 |  |  | 2021 |
ASSETS |  |  |  |  |  |  |  |
Current assets: |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 278,294 |  |  | $ | 263,865 |
Accounts receivable, less allowances of $238 and $218, respectively |  |  | 22,636 |  |  |  | 23,787 |
Inventories, net |  |  | 12,117 |  |  |  | 11,178 |
Prepaid expenses and other |  |  | 6,357 |  |  |  | 4,919 |
Total current assets |  |  | 319,404 |  |  |  | 303,749 |
Property, plant and equipment, net |  |  | 22,392 |  |  |  | 21,998 |
Deferred tax asset |  |  | 1,862 |  |  |  | 616 |
Other assets |  |  | 1,979 |  |  |  | 2,530 |
Intangibles, net |  |  | 103,488 |  |  |  | 111,741 |
Goodwill |  |  | 159,977 |  |  |  | 160,841 |
Total assets |  | $ | 609,102 |  |  | $ | 601,475 |
LIABILITIES AND STOCKHOLDERS’ EQUITY |  |  |  |  |  |  |  |
Current liabilities: |  |  |  |  |  |  |  |
Accounts payable |  | $ | 4,463 |  |  | $ | 4,473 |
Accrued payroll and benefits |  |  | 5,650 |  |  |  | 9,388 |
Unearned revenues |  |  | 9,741 |  |  |  | 8,777 |
Other accrued expenses |  |  | 8,836 |  |  |  | 9,945 |
Total current liabilities |  |  | 28,690 |  |  |  | 32,583 |
Deferred tax liability |  |  | 11,642 |  |  |  | 16,275 |
Other long-term liabilities |  |  | 436 |  |  |  | 715 |
Convertible senior notes, net of discounts and debt issuance costs |  |  | 168,917 |  |  |  | 145,675 |
Total liabilities |  |  | 209,685 |  |  |  | 195,248 |
Stockholders’ equity: |  |  |  |  |  |  |  |
Common stock, no par value; authorized 25,000,000 shares; issued and outstanding, 5,223,232 and 5,140,568 shares, respectively |  |  | 302,234 |  |  |  | 317,652 |
Retained earnings |  |  | 82,199 |  |  |  | 72,459 |
Accumulated other comprehensive income |  |  | 14,984 |  |  |  | 16,116 |
Total stockholders’ equity |  |  | 399,417 |  |  |  | 406,227 |
Total liabilities and stockholders’ equity |  | $ | 609,102 |  |  | $ | 601,475 |

See accompanying notes to Condensed Consolidated Financial Statements.

Page 1

Table of Contents

Mesa Laboratories, Inc.

Condensed Consolidated Statements of Income

(unaudited)

(in thousands, except per share data)

|  | Three Months Ended September 30, |  |  | Six Months Ended September 30, |
|  | 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
Revenues |  | $ | 35,840 |  |  | $ | 31,860 |  |  | $ | 70,760 |  |  | $ | 61,801 |
Cost of revenues |  |  | 12,700 |  |  |  | 10,575 |  |  |  | 25,409 |  |  |  | 20,176 |
Gross profit |  |  | 23,140 |  |  |  | 21,285 |  |  |  | 45,351 |  |  |  | 41,625 |
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Selling |  |  | 4,643 |  |  |  | 3,786 |  |  |  | 9,501 |  |  |  | 7,861 |
General and administrative |  |  | 11,683 |  |  |  | 10,615 |  |  |  | 23,102 |  |  |  | 20,714 |
Research and development |  |  | 2,613 |  |  |  | 2,414 |  |  |  | 5,424 |  |  |  | 5,010 |
Total operating expenses |  |  | 18,939 |  |  |  | 16,815 |  |  |  | 38,027 |  |  |  | 33,585 |
Operating income |  |  | 4,201 |  |  |  | 4,470 |  |  |  | 7,324 |  |  |  | 8,040 |
Nonoperating expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest expense and amortization of debt discount |  |  | 815 |  |  |  | 1,934 |  |  |  | 1,629 |  |  |  | 3,853 |
Other (income) expense, net |  |  | (1,157 | ) |  |  | 152 |  |  |  | (266 | ) |  |  | 1,049 |
Total nonoperating (income) expense |  |  | (342 | ) |  |  | 2,086 |  |  |  | 1,363 |  |  |  | 4,902 |
Earnings before income taxes |  |  | 4,543 |  |  |  | 2,384 |  |  |  | 5,961 |  |  |  | 3,138 |
Income tax provision (benefit) |  |  | 823 |  |  |  | (295 | ) |  |  | 246 |  |  |  | (758 | )
Net income |  | $ | 3,720 |  |  | $ | 2,679 |  |  | $ | 5,715 |  |  | $ | 3,896 |
Earnings per share: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 0.71 |  |  | $ | 0.52 |  |  | $ | 1.10 |  |  | $ | 0.81 |
Diluted |  | $ | 0.70 |  |  | $ | 0.51 |  |  | $ | 1.07 |  |  | $ | 0.79 |
Weighted-average common shares outstanding: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  | 5,211 |  |  |  | 5,110 |  |  |  | 5,182 |  |  |  | 4,821 |
Diluted |  |  | 5,344 |  |  |  | 5,241 |  |  |  | 5,324 |  |  |  | 4,958 |

See accompanying notes to Condensed Consolidated Financial Statements.

Page 2

Table of Contents

Mesa Laboratories, Inc.

Condensed Consolidated Statements of Comprehensive (Loss) Income

(unaudited)

(in thousands)

|  | Three Months Ended September 30, |  |  | Six Months Ended September 30, |
|  | 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
Net income |  | $ | 3,720 |  |  | $ | 2,679 |  |  | $ | 5,715 |  |  | $ | 3,896 |
Other comprehensive (loss) income: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency translation adjustments |  |  | (6,503 | ) |  |  | 5,262 |  |  |  | (1,132 | ) |  |  | 18,122 |
Comprehensive (loss) income |  | $ | (2,783 | ) |  | $ | 7,941 |  |  | $ | 4,583 |  |  | $ | 22,018 |

See accompanying notes to Condensed Consolidated Financial Statements.

Page 3

Table of Contents

Mesa Laboratories, Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited)

(in thousands)

|  | Six Months Ended September 30, |
|  | 2021 |  |  | 2020 |
Cash flows from operating activities: |  |  |  |  |  |  |  |
Net income |  | $ | 5,715 |  |  | $ | 3,896 |
Adjustments to reconcile net income to net cash provided by operating activities: |  |  |  |  |  |  |  |
Depreciation and amortization |  |  | 8,849 |  |  |  | 8,333 |
Stock-based compensation expense |  |  | 4,236 |  |  |  | 3,276 |
Non-cash interest and debt amortization |  |  | 443 |  |  |  | 2,667 |
Other |  |  | (224 | ) |  |  | 321 |
Cash (used in) provided by changes in operating assets and liabilities: |  |  |  |  |  |  |  |
Accounts receivable, net |  |  | 1,065 |  |  |  | 3,077 |
Inventories, net |  |  | (808 | ) |  |  | (464 | )
Prepaid expenses and other assets |  |  | (1,473 | ) |  |  | (1,941 | )
Accounts payable |  |  | (167 | ) |  |  | (1,604 | )
Accrued liabilities and taxes payable |  |  | (4,596 | ) |  |  | (4,811 | )
Unearned revenues |  |  | 983 |  |  |  | (140 | )
Net cash provided by operating activities |  |  | 14,023 |  |  |  | 12,610 |
Cash flows from investing activities: |  |  |  |  |  |  |  |
Purchases of property, plant and equipment |  |  | (1,591 | ) |  |  | (707 | )
Net cash (used in) investing activities |  |  | (1,591 | ) |  |  | (707 | )
Cash flows from financing activities: |  |  |  |  |  |  |  |
Proceeds from the issuance of common stock, net |  |  | - |  |  |  | 145,935 |
Dividends |  |  | (1,658 | ) |  |  | (1,522 | )
Proceeds from the exercise of stock options |  |  | 3,081 |  |  |  | 2,701 |
Payments of contingent consideration |  |  | - |  |  |  | (10 | )
Net cash provided by financing activities |  |  | 1,423 |  |  |  | 147,104 |
Effect of exchange rate changes on cash and cash equivalents |  |  | 574 |  |  |  | 1,537 |
Net increase in cash and cash equivalents |  |  | 14,429 |  |  |  | 160,544 |
Cash and cash equivalents at beginning of period |  |  | 263,865 |  |  |  | 81,380 |
Cash and cash equivalents at end of period |  | $ | 278,294 |  |  | $ | 241,924 |

See accompanying notes to Condensed Consolidated Financial Statements.

Page 4

Table of Contents

Mesa Laboratories, Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(unaudited)

(dollars in thousands, except per share data)

|  | Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Number of Shares |  |  | Amount |  |  | Retained Earnings |  |  | AOCI* |  |  | Total |
March 31, 2021 |  |  | 5,140,568 |  |  | $ | 317,652 |  |  | $ | 72,459 |  |  | $ | 16,116 |  |  | $ | 406,227 |
Exercise of stock options and vesting of restricted stock units |  |  | 58,324 |  |  |  | 1,089 |  |  |  | - |  |  |  | - |  |  |  | 1,089 |
Dividends paid, $0.16 per share |  |  | - |  |  |  | - |  |  |  | (824 | ) |  |  | - |  |  |  | (824 | )
Stock-based compensation expense |  |  | - |  |  |  | 2,197 |  |  |  | - |  |  |  | - |  |  |  | 2,197 |
Foreign currency translation |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 5,371 |  |  |  | 5,371 |
Cumulative adjustment due to adoption of ASU 2020-06 |  |  | - |  |  |  | (22,735 | ) |  |  | 5,683 |  |  |  | - |  |  |  | (17,052 | )
Net income |  |  | - |  |  |  | - |  |  |  | 1,995 |  |  |  | - |  |  |  | 1,995 |
June 30, 2021 |  |  | 5,198,892 |  |  | $ | 298,203 |  |  | $ | 79,313 |  |  | $ | 21,487 |  |  | $ | 399,003 |
Exercise of stock options and vesting of restricted stock units |  |  | 24,340 |  |  |  | 1,992 |  |  |  | - |  |  |  | - |  |  |  | 1,992 |
Dividends paid, $0.16 per share |  |  | - |  |  |  | - |  |  |  | (834 | ) |  |  | - |  |  |  | (834 | )
Stock-based compensation expense |  |  | - |  |  |  | 2,039 |  |  |  | - |  |  |  | - |  |  |  | 2,039 |
Foreign currency translation |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (6,503 | ) |  |  | (6,503 | )
Net income |  |  | - |  |  |  | - |  |  |  | 3,720 |  |  |  | - |  |  |  | 3,720 |
September 30, 2021 |  |  | 5,223,232 |  |  | $ | 302,234 |  |  | $ | 82,199 |  |  | $ | 14,984 |  |  | $ | 399,417 |

|  | Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Number of Shares |  |  | Amount |  |  | Retained Earnings |  |  | AOCI* |  |  | Total |
March 31, 2020 |  |  | 4,387,140 |  |  | $ | 158,023 |  |  | $ | 72,359 |  |  | $ | (10,369 | ) |  | $ | 220,013 |
Proceeds from the issuance of common stock, net of issuance costs of $9,315 |  |  | 690,000 |  |  |  | 145,935 |  |  |  | - |  |  |  | - |  |  |  | 145,935 |
Exercise of stock options and vesting of restricted stock units |  |  | 25,799 |  |  |  | 1,654 |  |  |  | - |  |  |  | - |  |  |  | 1,654 |
Dividends paid, $0.16 per share |  |  | - |  |  |  | - |  |  |  | (704 | ) |  |  | - |  |  |  | (704 | )
Stock-based compensation expense |  |  | - |  |  |  | 1,268 |  |  |  | - |  |  |  | - |  |  |  | 1,268 |
Foreign currency translation |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 12,860 |  |  |  | 12,860 |
Adoption of accounting standards, net |  |  | - |  |  |  | - |  |  |  | (9 | ) |  |  | - |  |  |  | (9 | )
Net income |  |  | - |  |  |  | - |  |  |  | 1,217 |  |  |  | - |  |  |  | 1,217 |
June 30, 2020 |  |  | 5,102,939 |  |  | $ | 306,880 |  |  | $ | 72,863 |  |  | $ | 2,491 |  |  | $ | 382,234 |
Exercise of stock options and vesting of restricted stock units |  |  | 14,502 |  |  |  | 1,047 |  |  |  | - |  |  |  | - |  |  |  | 1,047 |
Dividends paid, $0.16 per share |  |  | - |  |  |  | - |  |  |  | (818 | ) |  |  | - |  |  |  | (818 | )
Stock-based compensation expense |  |  | - |  |  |  | 2,008 |  |  |  | - |  |  |  | - |  |  |  | 2,008 |
Foreign currency translation |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 5,262 |  |  |  | 5,262 |
Net income |  |  | - |  |  |  | - |  |  |  | 2,679 |  |  |  | - |  |  |  | 2,679 |
September 30, 2020 |  |  | 5,117,441 |  |  | $ | 309,935 |  |  | $ | 74,724 |  |  | $ | 7,753 |  |  | $ | 392,412 |

*Accumulated Other Comprehensive Income (Loss).

See accompanying notes to Condensed Consolidated Financial Statements.

Page 5

Table of Contents

Mesa Laboratories, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(dollar and share amounts in thousands, unless otherwise specified)

Note 1. Description of Business and Summary of Significant Accounting Policies

Description of Business

In this quarterly report on Form 10-Q, Mesa Laboratories, Inc., a Colorado corporation, together with its subsidiaries is collectively referred to as “we,” “us,” “our,” the “Company” or “Mesa.”

We are a multinational manufacturer, developer, and seller of life science tools and critical quality control products and services, many of which are sold into niche markets that are driven by regulatory requirements. We have manufacturing operations in the United States and Europe, and our products are marketed by our sales personnel in North America, Europe, and Asia, and by independent distributors in these areas as well as throughout the rest of the world. We prefer markets in which we can establish a strong presence and achieve high gross margins.

As of September 30, 2021, we managed our operations in four reportable segments, or divisions. Our Sterilization and Disinfection Control division manufactures and sells biological, cleaning, and chemical indicators which are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. The division also provides testing and laboratory services, mainly to the dental industry. Our Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Immunoassays and peptide synthesis solutions accelerate the discovery, development, and manufacturing of biotherapeutic drugs. Our Instruments division designs, manufactures, and markets quality control hardware and disposable products utilized in the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, and environmental air sampling industries. Our Continuous Monitoring division designs, develops, and markets systems which are used to monitor various environmental parameters such as temperature, humidity, and differential pressure to ensure that critical storage and processing conditions are maintained in hospitals, pharmaceutical and medical device manufacturing facilities, blood banks, pharmacies, and laboratory environments. Non-reportable operating segments and unallocated corporate expenses are reported within Corporate and Other.

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of management, such unaudited information includes all adjustments, consisting of normal recurring adjustments necessary for a fair presentation of our financial position and results of operations. The results of operations for the interim periods are not necessarily indicative of results that may be achieved for the entire year. The year-end Condensed Consolidated Balance Sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. This quarterly report should be read in conjunction with the consolidated financial statements included in our annual report on Form 10-K for the year ended March 31, 2021.

Certain prior year amounts have been reclassified in order to conform to the current year presentation.

Our fiscal year ends on March 31. References in this Quarterly Report to a particular “year” or “year-end” mean our fiscal year, references to the first quarter of fiscal year 2022 refer to the period from April 1, 2021 through June 30, 2021, and references to the second quarter of fiscal year 2022 refer to the period from July 1, 2021 through September 30, 2021. References to “fiscal year 2021” refer to the fiscal year ended March 31, 2021, and to “fiscal year 2022” refer to the fiscal year ending March 31, 2022.

Risks and Uncertainties

The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the reporting date and revenues and expenses during the reporting periods. These estimates represent management's judgement about the outcome of future events. The current global business environment continues to be impacted directly and indirectly by the effects of the novel coronavirus ("COVID-19") and its variations, and it is not possible to accurately predict the future impact of COVID-19. However, we have reviewed the estimates used in preparing the financial statements and have identified the following factors that have a reasonable possibility of being materially affected by the impacts of COVID-19 during the near term:

● | Estimates regarding the future financial performance of the business used in the impairment tests for goodwill and long-lived assets acquired in a business combination; however, we have identified no triggering events since our impairment analysis was completed during the quarter ended March 31, 2021;

● | Estimates regarding the recoverability of deferred tax assets and estimates regarding cash needs and associated indefinite reinvestment assertions;

● | Estimates regarding recoverability of customer receivables;

● | Estimates of the net realizable value of inventory.

Page 6

Table of Contents

Recently Issued Accounting Pronouncements

We have reviewed all recently issued accounting pronouncements and have concluded that they are either not applicable to us or are not expected to have a significant impact on our consolidated financial statements.

Recently Adopted Accounting Pronouncements

In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2020-06, Debt with Conversion and Other Options and Derivatives and Hedging Accounting for Convertible Instruments and Contracts in an Entity's Own Equity ("ASU 2020-06"), which simplifies the accounting for certain financial instruments with characteristics of both liabilities and equity, such as our convertible senior notes, due 2025 (the "Notes"). ASU 2020-06 also enhances transparency and improves disclosures for convertible instruments and earnings per share guidance. It is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted at the beginning of any fiscal year after December 15, 2020. The update permits the use of either the modified retrospective or full retrospective method of transition.

We early adopted ASU 2020-06 effective April 1, 2021 on a modified retrospective basis, and our adoption of this standard had a material effect on our consolidated financial statements. Upon adoption, we derecognized the $22,735 equity conversion feature, net of taxes, that was recorded to common stock, and we derecognized the deferred tax liability of $5,747. We recorded an increase of $22,799 in aggregate to the Note balance as a result of the reversal of the separation of the debt and equity components of the convertible debt. The net effect of these adjustments, which represents $5,683 of historical non-cash interest expense, net of taxes, was recorded as an increase in the balance of beginning retained earnings as of April 1, 2021. The adoption of this standard will significantly decrease the amount of non-cash interest expense recognized in future periods as a result of eliminating the discount associated with the equity component. Our statements of cash flows reflect the lower non-cash interest expense in effect after the adoption of ASU 2020-06.

In each period in which the Notes have been outstanding, we have always intended to settle the Notes in shares of common stock rather than in cash, and therefore, we have applied the if-converted method to calculate the potentially dilutive impact of the Notes on earnings per share. In each reporting period, we have determined that the Notes were antidilutive. Due to decreases in non-cash interest expense that will result from the adoption of ASU 2020-06, it is likely the Notes will have a dilutive effect in future periods, which would decrease our diluted earnings per share.

Note 2. Revenue Recognition

We design, manufacture, market, sell, and maintain quality control instruments and software, consumables, and services driven primarily by the regulatory requirements of niche markets. Sales of hardware and software, such as medical meters, protein synthesizers, wireless sensor systems, and data loggers, are generally driven by our acquisition of new customers, growth of existing customers, or customers replacing existing equipment. Hardware sales may be offered with accompanying perpetual or annual software licenses, which in some cases are required for the hardware to function. We also offer on-demand and annual service contracts to support customers' use of our equipment. Our consumables, such as biological indicator test strips, are typically used on a standalone basis; however, some of our chemical solutions, such as protein synthesis and calibration solutions, are critical to the ongoing use of our instruments. Consumables are typically used on a one-time basis and require frequent replacement in our customers' operating cycles. We evaluate our revenues internally based on operating segment, the timing of revenue generation, and the nature of goods and services provided. Typically, discrete revenue is recognized at the shipping point or upon completion of the service, while contracted revenue is recognized over a period of time reflective of the performance obligation period in the applicable contract. Substantially all of our revenues and related receivables are generated from contracts with customers that are 12 months or less in duration.

Page 7

Table of Contents

The following tables present disaggregated revenues for the three and six months ended September 30, 2021 and 2020, respectively:

|  | Three Months Ended September 30, 2021 |
|  | Sterilization and Disinfection Control |  |  | Biopharmaceutical Development |  |  | Instruments |  |  | Continuous Monitoring |  |  | Total |
Discrete Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consumables |  | $ | 11,985 |  |  | $ | 5,218 |  |  | $ | 853 |  |  | $ | 7 |  |  | $ | 18,063 |
Hardware and Software |  |  | 85 |  |  |  | 3,472 |  |  |  | 4,485 |  |  |  | 2,063 |  |  |  | 10,105 |
Services |  |  | 493 |  |  |  | 850 |  |  |  | 1,632 |  |  |  | 1,349 |  |  |  | 4,324 |
Contracted Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Services and Software |  |  | 1,470 |  |  |  | 1,015 |  |  |  | - |  |  |  | 863 |  |  |  | 3,348 |
Total Revenues |  | $ | 14,033 |  |  | $ | 10,555 |  |  | $ | 6,970 |  |  | $ | 4,282 |  |  | $ | 35,840 |

|  | Three Months Ended September 30, 2020 |
|  | Sterilization and Disinfection Control |  |  | Biopharmaceutical Development |  |  | Instruments |  |  | Continuous Monitoring |  |  | Total |
Discrete Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consumables |  | $ | 9,518 |  |  | $ | 3,238 |  |  | $ | 715 |  |  | $ | 15 |  |  | $ | 13,486 |
Hardware and Software |  |  | 108 |  |  |  | 4,191 |  |  |  | 4,815 |  |  |  | 2,207 |  |  |  | 11,321 |
Services |  |  | 706 |  |  |  | 1,005 |  |  |  | 2,028 |  |  |  | 614 |  |  |  | 4,353 |
Contracted Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Services and Software |  |  | 1,220 |  |  |  | 697 |  |  |  | - |  |  |  | 783 |  |  |  | 2,700 |
Total Revenues |  | $ | 11,552 |  |  | $ | 9,131 |  |  | $ | 7,558 |  |  | $ | 3,619 |  |  | $ | 31,860 |

|  | Six Months Ended September 30, 2021 |
|  | Sterilization and Disinfection Control |  |  | Biopharmaceutical Development |  |  | Instruments |  |  | Continuous Monitoring |  |  | Total |
Discrete Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consumables |  | $ | 24,861 |  |  | $ | 8,826 |  |  | $ | 1,795 |  |  | $ | 17 |  |  | $ | 35,499 |
Hardware and Software |  |  | 245 |  |  |  | 7,029 |  |  |  | 9,723 |  |  |  | 3,907 |  |  |  | 20,904 |
Services |  |  | 1,194 |  |  |  | 1,432 |  |  |  | 3,014 |  |  |  | 2,202 |  |  |  | 7,842 |
Contracted Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Services and Software |  |  | 2,883 |  |  |  | 2,145 |  |  |  | - |  |  |  | 1,487 |  |  |  | 6,515 |
Total Revenues |  | $ | 29,183 |  |  | $ | 19,432 |  |  | $ | 14,532 |  |  | $ | 7,613 |  |  | $ | 70,760 |

|  | Six Months Ended September 30, 2020 |
|  | Sterilization and Disinfection Control |  |  | Biopharmaceutical Development |  |  | Instruments |  |  | Continuous Monitoring |  |  | Total |
Discrete Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consumables |  | $ | 21,002 |  |  | $ | 5,177 |  |  | $ | 1,523 |  |  | $ | 45 |  |  | $ | 27,747 |
Hardware and Software |  |  | 237 |  |  |  | 6,747 |  |  |  | 9,835 |  |  |  | 4,162 |  |  |  | 20,981 |
Services |  |  | 956 |  |  |  | 1,787 |  |  |  | 3,880 |  |  |  | 1,145 |  |  |  | 7,768 |
Contracted Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Services and Software |  |  | 2,424 |  |  |  | 1,369 |  |  |  | - |  |  |  | 1,512 |  |  |  | 5,305 |
Total Revenues |  | $ | 24,619 |  |  | $ | 15,080 |  |  | $ | 15,238 |  |  | $ | 6,864 |  |  | $ | 61,801 |

Page 8

Table of Contents

Revenues from external customers are attributed to individual countries based upon the locations to which the products are shipped or exported, as follows:

|  | Three Months Ended September |  |  | Six Months Ended September 30, |
|  | 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
United States |  | $ | 19,384 |  |  | $ | 11,222 |  |  | $ | 37,839 |  |  | $ | 27,594 |
Foreign |  |  | 16,456 |  |  |  | 20,638 |  |  |  | 32,921 |  |  |  | 34,207 |
Total revenues |  | $ | 35,840 |  |  | $ | 31,860 |  |  | $ | 70,760 |  |  | $ | 61,801 |

No foreign country exceeds 10% of total revenues.

Contract Balances

Our contracts have varying payment terms and conditions. Some customers prepay for products and services, resulting in unearned revenues or customer deposits, called contract liabilities, which are included within other accrued expenses and unearned revenues in the accompanying Condensed Consolidated Balance Sheets. We did not have any contract assets as of September 30, 2021 or March 31, 2021. Unbilled receivables, which are not classified as contract assets, represent arrangements in which sales have been recorded prior to billing and right to payment is unconditional.

A summary of contract liabilities is as follows:

Contract liabilities as of March 31, 2021 |  | $ | 8,994 |
Prior year liabilities recognized in revenues during the six months ended September 30, 2021 |  |  | (3,910 | )
Contract liabilities added during the six months ended September 30, 2021, net of revenues recognized |  |  | 5,592 |
Contract liabilities balance as of September 30, 2021 |  | $ | 10,676 |

Note 3. Fair Value Measurements

Our financial instruments consist primarily of cash and cash equivalents, trade accounts receivable, obligations under trade accounts payable, and debt. Due to their short-term nature, the carrying values for cash and cash equivalents, trade accounts receivable, and trade accounts payable approximate fair value. We measure our cash equivalents at fair value using quoted market prices in an active market, and we classify them within Level 1 of the fair value hierarchy. Cash and cash equivalents on our Condensed Consolidated Balance Sheets included $240,822 and $230,822 in a money market account as of September 30, 2021 and March 31, 2021, respectively.

During fiscal year 2020, we issued $172,500 aggregate principal of 1.375% convertible senior notes due August 15, 2025. We estimate the fair value of the Notes based on Level 2 inputs of the last actively traded price or market observable input before the end of the reporting period. The estimated fair value and carrying value of the Notes are as follows:

|  | September 30, 2021 |  |  | March 31, 2021 |
|  | Carrying Value |  |  | Fair Value (Level 2) |  |  | Carrying Value |  |  | Fair Value (Level 2) |
Notes |  | $ | 168,917 |  |  | $ | 211,097 |  |  | $ | 145,675 |  |  | $ | 188,780 |

The carrying value of the Notes increased as a result of the adoption of ASU 2020-06, discussed further in Note 1. "Description of Business and Summary of Significant Accounting Policies" and Note 6. "Indebtedness."

Assets recognized or disclosed at fair value in the unaudited condensed consolidated financial statements on a nonrecurring basis include items such as property and equipment, operating lease assets, goodwill, and other intangible assets. These assets are measured at fair value if determined to be impaired. There were no transfers between the levels of the fair value hierarchy during the three and six months ended September 30, 2021 or the three and six months ended September 30, 2020.

Cash and cash equivalents and accounts receivables are the financial instruments that subject us to the highest concentration of credit risk. It is our policy to invest in highly liquid cash equivalent financial instruments with high credit ratings, and to maintain low single issuer exposure (except U.S. treasuries). Concentration of credit risk with respect to accounts receivable is limited to customers to whom we make significant sales. We reserve an allowance for potential write-offs of accounts receivable using historical collection experience and current and expected future economic and market conditions, but we have not written off any significant accounts to date. To manage credit risk, we consider the creditworthiness of new and existing customers, and we regularly review outstanding balances and payment histories. We may require pre-payments from customers under certain circumstances and may limit future purchases until payments are made on past due amounts.

Note 4. Inventories, Net

Inventories consist of the following:

|  | September 30, 2021 |  |  | March 31, 2021 |
Raw materials |  | $ | 7,610 |  |  | $ | 5,755 |
Work in process |  |  | 423 |  |  |  | 426 |
Finished goods |  |  | 4,084 |  |  |  | 4,997 |
Inventories, net |  | $ | 12,117 |  |  | $ | 11,178 |

Raw materials inventory was higher as of September 30, 2021 compared to March 31, 2021, primarily because we ordered higher than usual quantities of some components during the second quarter of fiscal year 2022 to mitigate supply chain risks.

Page 9

Table of Contents

Note 5. Goodwill and Intangible Assets, Net

Finite-lived intangible assets consist of the following:

|  | September 30, 2021 |  |  | March 31, 2021 |
|  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net Carrying Amount |  |  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net Carrying Amount |
Intellectual property |  | $ | 21,094 |  |  | $ | (9,409 | ) |  | $ | 11,685 |  |  | $ | 21,201 |  |  | $ | (8,595 | ) |  | $ | 12,606 |
Trade names |  |  | 8,574 |  |  |  | (3,265 | ) |  |  | 5,309 |  |  |  | 8,612 |  |  |  | (3,129 | ) |  |  | 5,483 |
Customer relationships |  |  | 144,869 |  |  |  | (58,459 | ) |  |  | 86,410 |  |  |  | 145,754 |  |  |  | (52,206 | ) |  |  | 93,548 |
Non-compete agreements |  |  | 1,299 |  |  |  | (1,215 | ) |  |  | 84 |  |  |  | 1,299 |  |  |  | (1,195 | ) |  |  | 104 |
Total |  | $ | 175,836 |  |  | $ | (72,348 | ) |  | $ | 103,488 |  |  | $ | 176,866 |  |  | $ | (65,125 | ) |  | $ | 111,741 |

Amortization expense for finite-lived intangible assets acquired in a business combination was $3,757 and $7,573 for the three and six months ended September 30, 2021, respectively, and $3,512 and $6,866 for the three and six months ended September 30, 2020, respectively. During the quarter ended June 30, 2020, we reduced the value of our intangible assets due to a purchase price adjustment that resulted in a cumulative effect net decrease to amortization expense of $334.

For the following fiscal years ending March 31, amortization expense is estimated as follows:

Remainder of 2022 |  |  | 7,398 |
2023 |  |  | 14,622 |
2024 |  |  | 14,107 |
2025 |  |  | 12,515 |
2026 |  |  | 11,731 |

The change in the carrying amount of goodwill was as follows:

|  | Sterilization and Disinfection Control |  |  | Biopharmaceutical Development |  |  | Instruments |  |  | Continuous Monitoring |  |  | Total |
March 31, 2021 |  | $ | 30,153 |  |  | $ | 93,399 |  |  | $ | 19,186 |  |  | $ | 18,103 |  |  | $ | 160,841 |
Effect of foreign currency translation |  |  | (100 | ) |  |  | (752 | ) |  |  | (12 | ) |  |  | - |  |  |  | (864 | )
September 30, 2021 |  | $ | 30,053 |  |  | $ | 92,647 |  |  | $ | 19,174 |  |  | $ | 18,103 |  |  | $ | 159,977 |

Note 6. Indebtedness

Credit Facility

On March 5, 2021, we entered into a four-year senior secured credit agreement that includes 1) a revolving credit facility in an aggregate principal amount of up to $75,000, 2) a swingline loan in an aggregate principal amount not exceeding $5,000, and 3) letters of credit in an aggregate stated amount not exceeding $2,500 at any time. The Credit Facility also provides for an incremental term loan or an increase in revolving commitments in an aggregate principal amount of at a minimum $25,000 and at a maximum $75,000, subject to the satisfaction of certain conditions and lender considerations (together, the available facilities are referred to as the "Credit Facility").

The Credit Facility bears interest at either a base rate or a Eurodollar rate, plus an applicable spread. The balance of unamortized customary lender fees was $567 and $650 as of September 30, 2021 and March 31, 2021, respectively. On our Consolidated Balance Sheets, the short term portion is recorded within prepaid expenses and other, and the long term portion is recorded in other assets. The fees are being expensed on a straight line basis over the life of the agreement.

The most restrictive financial covenants include a maximum leverage ratio of 5.50 to 1.00 for the first four testing dates on which the line of credit is outstanding; 5.0 to 1.0 on each of the fifth, sixth, seventh, and eighth testing dates; and 4.5 to 1.0 on each testing date following the eighth testing date, except that we may have a leverage ratio of 5.75 to 1.0 for a period of four consecutive quarters following a permitted acquisition. The Credit Facility also stipulates a minimum fixed charge coverage ratio of 1.25 to 1.0. Other covenants include restrictions on our ability to incur debt, grant liens, make fundamental changes, engage in certain transactions with affiliates, or conduct asset sales. As of September 30, 2021, we were in compliance with all required covenants.

As of and throughout the three and six months ended September 30, 2021, we had no outstanding balance under the Credit Facility. On October 18, 2021, we drew $70,000 under our line of credit to provide a portion of the cash needed to complete the acquisition of Agena Biosciences, Inc. ("Agena") as further discussed in Note 11. "Significant Transactions." We are obligated to pay quarterly unused commitment fees of between 0.15% and 0.35% of the Credit Facility’s aggregate principal amount, based on our leverage ratio. Since the Credit Facility's inception, the rate applied to our unused commitment fees has been 0.15%. We incurred unused commitment fees of $28 and $57 during the three and six months ended September 30, 2021, respectively, and $0 and $0 during the three and six months ended September 30, 2020, respectively.

Page 10

Table of Contents

Convertible Notes

On August 12, 2019, we issued an aggregate principal amount of $172,500 of convertible senior notes. The Notes mature on August 15, 2025, unless earlier repurchased or converted, and bear interest at a rate of 1.375% payable semi-annually in arrears on February 15 and August 15 each year beginning on February 15, 2020. The Notes are initially convertible at a conversion rate of 3.5273 shares of common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $283.50 per share of common stock. Noteholders may convert their Notes at their option only in the following circumstances:

(i) |  |  | during any calendar quarter commencing after the calendar quarter ended on December 31, 2019 (and only during such calendar quarter), if the last reported sale price per share of our common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter;
(ii) |  |  | during the five consecutive business days immediately after any 10 consecutive trading day period (such 10 consecutive trading day period, the “measurement period”) in which the trading price per $1,000 principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day;
(iii) |  |  | upon the occurrence of certain corporate events or distributions on our common stock, including certain distributions, the occurrence of a fundamental change (as defined in the indenture governing the Notes) or a transaction resulting in the Company’s common stock converting into other securities or property or assets; and
(iv) |  |  | at any time from, and including, April 15, 2025 until the close of business on the second scheduled trading day immediately before the maturity date.

Upon conversion, we will pay or deliver, as the case may be, cash, shares of our common stock, or a combination of cash and shares of our common stock, at our election. Our current intent is to settle conversions entirely in shares of common stock. We will reevaluate this policy from time to time as we receive conversion notices from note holders. The circumstances necessary for conversion were not met during the three or six months ended September 30, 2021. As of September 30, 2021, the Notes are classified as a long-term liability on our Condensed Consolidated Balance Sheets as the circumstances necessary for conversion were not satisfied as of the end of the period. The if-converted value of the Notes did not exceed the principal balance as of September 30, 2021.

Debt issuance costs related to the Notes are comprised of discounts and commissions payable to the initial purchasers of $5,175 and third party offering costs of $255. The debt issuance costs are being amortized to interest expense using the effective interest method over the six-year contractual term of the Notes.

Due to our adoption of ASU 2020-06 on April 1, 2021, we no longer bifurcate the Notes into a liability and an equity component in our Condensed Consolidated Balance Sheets (see Note 1. "Description of Business and Summary of Significant Accounting Policies"). The Notes are accounted for entirely as a liability, and the issuance costs of the Notes are accounted for wholly as debt issuance costs. The equity conversion feature that was recorded to common stock, as well as the unamortized debt discount and amortization expense attributable to equity, have been derecognized.

The net carrying amount of the Notes was as follows:

|  | September 30, 2021 |  |  | March 31, 2021 |
Principal outstanding |  | $ | 172,500 |  |  | $ | 172,500 |
Unamortized debt discount attributable to equity |  |  | - |  |  |  | (23,497 | )
Unamortized debt issuance costs |  |  | (3,583 | ) |  |  | (3,328 | )
Net carrying value |  | $ | 168,917 |  |  | $ | 145,675 |

We recognized interest expense on the Notes as follows:

|  | Three Months Ended September 30, |  |  | Six Months Ended September 30, |
|  | 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
Coupon interest expense at 1.375% |  | $ | 593 |  |  | $ | 593 |  |  | $ | 1,186 |  |  | $ | 1,186 |
Amortization of debt discounts and issuance costs |  |  | 222 |  |  |  | 1,341 |  |  |  | 443 |  |  |  | 2,667 |
Total |  | $ | 815 |  |  | $ | 1,934 |  |  | $ | 1,629 |  |  | $ | 3,853 |

The effective interest rate on the notes is approximately 1.9%. Prior to the adoption of ASU 2020-06, the effective interest rate was approximately 5.5%.

Note 7. Stockholders' Equity

Stock-Based Compensation

During the three months ended September 30, 2021, our shareholders approved the Mesa Laboratories, Inc. 2021 Equity Incentive Plan (the "2021 Equity Plan"), which authorizes the issuance of 330 shares of common stock to eligible participants. For the purpose of counting the shares remaining under the 2021 Equity Plan, each share underlying a stock option or a full value award (such as restricted stock units and performance shares) counts as one share used. The 2021 Equity Plan is administered by the Compensation Committee of the Board of Directors, which has the authority to grant equity awards, or to delegate its authority under the plan to make grants (subject to certain legal and regulatory restrictions), including the authority to determine the individuals to whom awards will be granted, the type of awards and when the awards are to be granted, the number of shares to be covered by each award, the vesting schedule, and all other terms and conditions of the awards.

Our 2021 Equity Plan includes retiree provisions, which result in the acceleration of stock-based compensation expense for retiree-eligible participants.

Page 11

Table of Contents

The exercise price for stock awards granted under the 2021 Equity Plan cannot be less than fair market value at the date of grant. Shares issued during the six months ended September 30, 2021 were issued in connection with the 2021 Equity Plan.

Amounts recognized related to stock-based compensation are as follows:

|  | Three Months Ended September 30, |  |  | Six Months Ended September 30, |
|  | 2022 |  |  | 2021 |  |  | 2021 |  |  | 2020 |
Stock-based compensation expense |  | $ | 2,039 |  |  | $ | 2,008 |  |  | $ | 4,236 |  |  | $ | 3,276 |
Amount of income tax (benefit) recognized in earnings |  |  | (719 | ) |  |  | (522 | ) |  |  | (3,504 | ) |  |  | (1,447 | )
Stock-based compensation expense, net of tax |  | $ | 1,320 |  |  | $ | 1,486 |  |  | $ | 732 |  |  | $ | 1,829 |

Stock-based compensation expense is included in cost of revenues, selling, general and administrative, and research and development expense in the accompanying unaudited Condensed Consolidated Statements of Income.

The following is a summary of stock option award activity for the six months ended September 30, 2021:

|  | Stock Options |
|  | Shares Subject to Options |  |  | Weighted- Average Exercise Price per Share |  |  | Weighted-Average Remaining Contractual Life (Years) |  |  | Aggregate Intrinsic Value |
Outstanding as of March 31, 2021 |  |  | 253 |  |  | $ | 129.55 |  |  |  | 2.7 |  |  | $ | 28,856 |
Awards granted |  |  | 37 |  |  |  | 268.85 |  |  |  |  |  |  |  |  |
Awards forfeited or expired |  |  | (3 | ) |  |  | 173.29 |  |  |  |  |  |  |  |  |
Awards exercised |  |  | (37 | ) |  |  | 94.49 |  |  |  |  |  |  |  |  |
Outstanding as of September 30, 2021 |  |  | 250 |  |  | $ | 154.16 |  |  |  | 2.9 |  |  | $ | 37,092 |

The stock options granted during the six months ended September 30, 2021 vest in equal installments on September 1, 2022, June 15, 2023 and June 15, 2024.

The following is a summary of restricted stock unit ("RSU") award activity for the six months ended September 30, 2021:

|  | Time-Based Restricted Stock Units |  |  | Performance-Based Restricted Stock Units |
|  | Number of Shares |  |  | Weighted- Average Grant Date Fair Value per Share |  |  | Number of Shares |  |  | Weighted- Average Grant Date Fair Value per Share |
Outstanding as of March 31, 2021(1) |  |  | 37 |  |  | $ | 206.56 |  |  |  | 20 |  |  | $ | 207.88 |
Awards granted |  |  | 29 |  |  |  | 267.09 |  |  |  | - |  |  |  | - |
Performance adjustment(2) |  |  | - |  |  |  | - |  |  |  | 16 |  |  |  | 190.07 |
Awards forfeited |  |  | (1 | ) |  |  | 210.22 |  |  |  | - |  |  |  | - |
Awards distributed |  |  | (19 | ) |  |  | 208.13 |  |  |  | (28 | ) |  |  | 197.81 |
Outstanding as of September 30, 2021(1) |  |  | 46 |  |  | $ | 244.45 |  |  |  | 8 |  |  | $ | 202.00 |

(1) | Balances for performance-based restricted stock units ("PSUs") are reflected at target.

(2) | During the three months ended June 30, 2021, the fiscal year 2019 PSUs vested and were paid at 280% of target, based on actual performance results and completion of service conditions. In addition, the PSUs granted to employees of Gyros Protein Technologies Holding AB vested at 60% of target, following a modification of the performance targets by the Compensation Committee of the Board of Directors during fiscal year 2021.

The outstanding time-based RSUs vest and settle in shares of our common stock on a one-for-one basis. The substantial majority of the RSUs granted during the six months ended September 30, 2021 vest in equal installments on September 1, 2022, June 15, 2023 and June 15, 2024, except time-based RSUs issued to non-employee directors, which vest one year from the grant date. We recognize the expense relating to RSUs, net of estimated forfeitures, on a straight-line basis over the vesting period.

Page 12

Table of Contents

Performance-based RSUs vest upon completion of the service period described in the award agreement and based on achievement of the financial targets described in the award agreements. We recognize the expense relating to the performance-based RSUs based on the probable outcome of achievement of the financial targets on a straight-line basis over the service period. During fiscal year 2020, we awarded 8 PSUs (the "FY 20 PSUs") that are subject to both service and performance conditions to eligible employees. The FY 20 PSUs had a grant date fair value of $202.00 per share and vest based on our achievement of specific performance criteria for the three-year period from April 1, 2019 through March 31, 2022 and on a pro-rata basis after 12 months of continued service through June 15, 2022. The quantity of shares that will be issued upon vesting will range from 0% to 200% of the targeted number of shares; if the defined minimum targets are not met, then no shares will vest. Based on actual and projected performance through the quarter ended September 30, 2021, we estimate that 6 FY 20 PSUs will vest.

During the three months ended June 30, 2021, the Compensation Committee of the Board of Directors modified a time-based restricted stock award granted to our Chief Executive Officer during fiscal year 2017, distributing 3 remaining outstanding shares effective June 8, 2021. The original award required vesting of 1 awards on each: March 20, 2022, 2023, and 2024. As a result of the modification, we recognized the previously unrecognized compensation cost of $351 during the three months ended June 30, 2021.

Public Offering of Common Stock

On June 12, 2020, we completed the sale and issuance of 600 shares of our common stock and on June 19, 2020, our underwriters exercised in full their option to purchase an additional 90 shares of our common stock. The offering price to the public was $225.00 per share. The total proceeds we received from the offering, net of underwriting discounts and commissions and other offering expenses was $145,935.

Note 8. Earnings Per Share

Basic earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding during the reporting period. Diluted earnings per share (“diluted EPS”) is computed similarly to basic earnings per share, except that it includes the potential dilution that could occur if dilutive securities were exercised. Potentially dilutive securities include stock options and RSUs, including RSUs that contain performance conditions which have been achieved as of the reporting period (collectively “stock awards”), as well as common shares underlying our convertible senior notes. Stock awards are excluded from the calculation of diluted EPS in the event that they are subject to performance conditions that have not yet been achieved or are antidilutive. Diluted EPS considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would then have an antidilutive effect.

The impact of the assumed conversion of the Notes calculated under the if-converted method was anti-dilutive, and as such, shares underlying the Notes were excluded from the diluted EPS calculation for three and six months ended September 30, 2021.

The following table presents a reconciliation of the denominators used in the computation of basic and diluted earnings per share:

|  | Three Months Ended September 30, |  |  | Six Months Ended September 30, |
|  | 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
Net income available for shareholders |  | $ | 3,720 |  |  | $ | 2,679 |  |  | $ | 5,715 |  |  | $ | 3,896 |
Weighted average outstanding shares of common stock |  |  | 5,211 |  |  |  | 5,110 |  |  |  | 5,182 |  |  |  | 4,821 |
Dilutive effect of stock options |  |  | 109 |  |  |  | 119 |  |  |  | 109 |  |  |  | 125 |
Dilutive effect of RSUs |  |  | 24 |  |  |  | 12 |  |  |  | 33 |  |  |  | 12 |
Fully diluted shares |  |  | 5,344 |  |  |  | 5,241 |  |  |  | 5,324 |  |  |  | 4,958 |
Basic earnings per share |  | $ | 0.71 |  |  | $ | 0.52 |  |  | $ | 1.10 |  |  | $ | 0.81 |
Diluted earnings per share |  | $ | 0.70 |  |  | $ | 0.51 |  |  | $ | 1.07 |  |  | $ | 0.79 |

The following stock awards were excluded from the calculation of diluted EPS:

|  | Three Months Ended September 30, |  |  | Six Months Ended September 30, |
|  | 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
Assumed conversion of convertible debt |  |  | 608 |  |  |  | 608 |  |  |  | 608 |  |  |  | 608 |
Stock awards that were anti-dilutive |  |  | 43 |  |  |  | 63 |  |  |  | 40 |  |  |  | 49 |
Stock awards subject to performance conditions |  |  | 8 |  |  |  | 21 |  |  |  | 8 |  |  |  | 19 |
Total stock awards excluded from diluted EPS |  |  | 659 |  |  |  | 692 |  |  |  | 656 |  |  |  | 676 |

Note 9. Income Taxes

For interim income tax reporting, we estimate our annual effective tax rate and apply this effective tax rate to our year-to-date pre-tax income. Each quarter, our estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. Additionally, the tax effects of significant unusual or infrequently occurring items are recognized as discrete items in the interim period in which the events occur. The impact of changes in tax laws or rates on deferred tax amounts, impairments of non-deductible goodwill, excess benefits from stock-based compensation, and changes in tax reserves resulting from the finalization of tax audits or reviews are examples of significant unusual or infrequently occurring items that are recognized as discrete items in the interim period in which the event occurs. There is a potential for volatility of the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, settlement with taxing authorities, and foreign currency fluctuations.

Page 13

Table of Contents

Our effective income tax rate was 4.1% for the six months ended September 30, 2021 and (24.2)% for the six months ended September 30, 2020. The effective tax rate for the six months ended September 30, 2021 differed from the statutory federal rate of 21% primarily due to the benefit of share-based payment awards for employees and foreign derived intangible income, partially offset by the limitations imposed by Section 162(m), and expenses for state income taxes.

The tax year ended December 31, 2018 for Gyros US, Inc., and its subsidiary, which we acquired as part of the Gyros Protein Technologies ("GPT") acquisition, is under examination by the IRS. Additionally, the tax year ended March 31, 2019 for Mesa Laboratories, Inc. is under review by the IRS. We expect the examinations to be completed during fiscal year 2022.

Since we are subject to audit by various taxing authorities, it is reasonably possible that the amount of unrecognized tax benefits will change during the next 12 months. However, we do not expect the change, if any, to have a material effect on our financial condition or results of operations within the next 12 months.

Note 10. Commitments and Contingencies

We review the adequacy of our legal reserves on a quarterly basis and establish reserves for loss contingencies that are both probable and reasonably estimable. As of September 30, 2021, there were no material legal reserves recorded on the accompanying unaudited Condensed Consolidated Balance Sheets.

Companies are required to collect and remit sales tax from certain customers if the company is determined to have nexus in a particular state. The determination of nexus varies by state and often requires technical knowledge of each jurisdiction's tax case law. During fiscal year 2021, we determined that certain subsidiaries of GPT had established nexus in various jurisdictions during prior periods without properly collecting and remitting sales tax, and in certain cases had collected sales tax and not remitted it. The estimated accrued liability for this matter is included in other accrued expenses on the Condensed Consolidated Balance Sheets. The balance was $2,700 and $2,714 as of September 30, 2021 and March 31, 2021, respectively. The balance decreased because we settled our obligations with certain states during the six months ended September 30, 2021, partially offset by additional taxes, interest, and penalties incurred. Approximately $1,899 of the liability is considered a preacquisition contingency and was included in purchase accounting.

Note 11. Significant Transactions

Agena Bioscience, Inc.

On October 20, 2021, we completed the acquisition of Agena. Agena is a leading clinical genomics tools company that develops, manufactures, and supplies highly sensitive, low-cost, high-throughput, genetic analysis solutions to clinical labs and development partners globally.

On the acquisition date, Agena shareholders were entitled to an aggregate cash purchase price of $300,000, subject to customary purchase price adjustments, and that amount was remitted to the paying agent or other third parties. We funded the transaction using cash on hand, combined with the proceeds from a $70,000 draw under our Credit Facility. Refer to Note 6. "Indebtedness" for additional details on our Credit Facility. The initial accounting for Agena is not complete due to the limited amount of time since the acquisition date. In an acquisition, U.S. GAAP requires the company to record all assets acquired and all liabilities assumed at the acquisition date fair value. We are in the process of preparing our preliminary purchase price allocation, including initial estimates for inventory, goodwill, and intangible assets.

Butler, New Jersey Closure

We completed the previously-announced closure of our Butler, New Jersey facility during the three months ended June 30, 2021. The facility was primarily used in the production of our gas flow calibration and air sampling equipment, which is part of our Instruments division. Our manufacturing facility in Lakewood, Colorado is currently undergoing renovations that will allow it to accommodate the production of the gas flow calibration and air sampling equipment. Consolidating the production of these products is expected to reduce facilities costs and streamline our use of lean manufacturing tools under central management to further encourage production efficiencies.

As a result of the facility consolidation, we incurred $77 of severance costs during the six months ended September 30, 2021 which were recorded to cost of revenues, selling, and general and administrative expense on the Consolidated Statement of Income. As of September 30, 2021, a total of $70 remained outstanding and accrued, which relates to severance costs. We do not expect to incur any material expenses related to the Butler, New Jersey consolidation in future periods.

Page 14

Table of Contents

Note 12. Segment Information

As of September 30, 2021, we had four reportable segments: Sterilization and Disinfection Control, Biopharmaceutical Development, Instruments, and Continuous Monitoring.

|  | Three Months Ended September 30, |  |  | Six Months Ended September 30, |
|  | 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
Total revenues (a) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sterilization and Disinfection Control |  | $ | 14,033 |  |  | $ | 11,552 |  |  | $ | 29,183 |  |  | $ | 24,619 |
Biopharmaceutical Development |  |  | 10,555 |  |  |  | 9,131 |  |  |  | 19,432 |  |  |  | 15,080 |
Instruments |  |  | 6,970 |  |  |  | 7,558 |  |  |  | 14,532 |  |  |  | 15,238 |
Continuous Monitoring |  |  | 4,282 |  |  |  | 3,619 |  |  |  | 7,613 |  |  |  | 6,864 |
Total revenues (a) |  | $ | 35,840 |  |  | $ | 31,860 |  |  | $ | 70,760 |  |  | $ | 61,801 |
Gross profit (loss) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sterilization and Disinfection Control |  | $ | 10,486 |  |  | $ | 8,770 |  |  | $ | 21,914 |  |  | $ | 18,790 |
Biopharmaceutical Development |  |  | 6,601 |  |  |  | 6,212 |  |  |  | 11,293 |  |  |  | 10,678 |
Instruments |  |  | 4,112 |  |  |  | 4,852 |  |  |  | 8,772 |  |  |  | 9,541 |
Continuous Monitoring |  |  | 2,016 |  |  |  | 1,368 |  |  |  | 3,468 |  |  |  | 2,552 |
Reportable segment gross profit |  |  | 23,215 |  |  |  | 21,202 |  |  |  | 45,447 |  |  |  | 41,561 |
Corporate and Other (b) |  |  | (75 | ) |  |  | 83 |  |  |  | (96 | ) |  |  | 64 |
Gross profit |  | $ | 23,140 |  |  | $ | 21,285 |  |  | $ | 45,351 |  |  | $ | 41,625 |
Reconciling Items: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating expenses |  |  | 18,939 |  |  |  | 16,815 |  |  |  | 38,027 |  |  |  | 33,585 |
Operating income |  |  | 4,201 |  |  |  | 4,470 |  |  |  | 7,324 |  |  |  | 8,040 |
Nonoperating (income) expense, net |  |  | (342 | ) |  |  | 2,086 |  |  |  | 1,363 |  |  |  | 4,902 |
Earnings before income taxes |  | $ | 4,543 |  |  | $ | 2,384 |  |  | $ | 5,961 |  |  | $ | 3,138 |

| (a) | Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.

| (b) | Non-reportable operating segments and unallocated corporate expenses are reported within Corporate and Other.

The following table sets forth inventories by reportable segment. Our chief operating decision maker is not provided with any other segment asset information.

|  | September 30, |  |  | March 31, |
|  | 2021 |  |  | 2021 |
Sterilization and Disinfection Control |  | $ | 2,187 |  |  | $ | 2,333 |
Biopharmaceutical Development |  |  | 3,706 |  |  |  | 4,162 |
Instruments |  |  | 4,566 |  |  |  | 3,253 |
Continuous Monitoring |  |  | 1,658 |  |  |  | 1,430 |
Total inventories |  | $ | 12,117 |  |  | $ | 11,178 |

Note 13. Subsequent Event

As disclosed in our Form 8-K filed on October 29, 2021, the Compensation Committee of Mesa's Board of Directors granted a special long-term equity award (the “Special Award”) to Gary Owens, Chief Executive Officer and Member of the Board of Directors on October 28, 2021. The Special Award consists of an award of performance stock units covering a target of 40,000 shares (“PSUs”) that is subject to both performance and service conditions. The performance period of the award is the three-year period from April 1, 2021 through March 31, 2024 and the service period is the period commencing October 28, 2021 and ending on October 27, 2024, October 27, 2025, and October 27, 2026 on which dates eligible PSUs will vest and be distributed to Mr. Owens.

Page 15

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in thousands, except per share amounts)

Forward Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The forward-looking statements in this Quarterly Report on Form 10-Q do not constitute guarantees of future performance. Investors are cautioned that statements in this Quarterly Report on Form 10-Q which are not strictly historical statements, including, without limitation, express or implied statements or guidance regarding current or future financial performance and position, potential impairment of future earnings, anticipated effects of, and future actions to be taken in response to, the COVID-19 pandemic; results of acquisitions; management’s strategy, plans and objectives for future operations or acquisitions, product development and sales; product research and development; regulatory approval; selling, general and administrative expenditures; intellectual property; development and manufacturing plans; availability of materials and components; and adequacy of capital resources and financing plans constitute forward-looking statements. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which the Company operates, and management’s beliefs and assumptions. In addition, other written and oral statements that constitute forward-looking statements may be made by the Company or on the Company’s behalf. Words such as “expect,” “intend,” “seek,” “plan,” “anticipate,” “believe,” “could,” “estimate,” “may,” “target,” “project,” or variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks associated with: the duration and impact of the COVID-19 pandemic and its adverse effects on our business; our ability to successfully grow our business, including as a result of acquisitions; the results on operations of acquisitions; our ability to consummate acquisitions at our historical rate and at appropriate prices, and our ability to effectively integrate acquired businesses and achieve desired results; the market acceptance of our products; technological or market viability of our products; reduced demand for our products; conditions in the global economy and the particular markets we serve; significant developments or uncertainties stemming from governments, including changes in trade policies and medical device regulations; the timely development and commercialization, and customer acceptance, of enhanced and new products and services; retirement of old products and customer migration to new products; projections of revenues, growth, operating results, profit margins, expenses, earnings, margins, tax rates, tax provisions, cash flows, liquidity, demand, and competition; the effects of additional actions taken to become more efficient or lower costs; restructuring activities; laws regulating fraud and abuse in the health care industry and the privacy and security of health and personal information; product liability; information security; outstanding claims, legal and regulatory proceedings; international business challenges including anti-corruption and sanctions laws; tax audits and assessments and other contingent liabilities; foreign currency exchange rates and fluctuations in those rates; general economic, industry, and capital markets conditions; the timing of any of the foregoing; assumptions underlying any of the foregoing; and any other statements that address events or developments that we intend or believe will or may occur in the future. Such risks and uncertainties also include those listed in Item 1A. “Risk Factors,” and elsewhere in this report. The foregoing list sets forth many, but not all, of the factors that could impact our ability to achieve results described in any forward-looking statements. We disclaim any obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise.

Business Overview

We are a multinational manufacturer, developer, and seller of life science tools and critical quality control products and services, many of which are sold into niche markets that are driven by regulatory requirements. We have manufacturing operations in the United States and Europe, and our products are marketed by our sales personnel in North America, Europe, and Asia, and by independent distributors in these areas as well as throughout the rest of the world. We prefer markets in which we can establish a strong presence and achieve high gross margins. As of September 30, 2021, we managed our operations in four reportable segments, or divisions: Sterilization and Disinfection Control, Biopharmaceutical Development, Instruments, and Continuous Monitoring, each of which are described further in "Results of Operations" below. Non-reportable operating segments and unallocated corporate expenses are reported within Corporate and Other.

Corporate Strategy

We strive to create shareholder value and further our purpose of Protecting the Vulnerable® by growing our business both organically and through acquisitions, by improving our operating efficiency, and by continuing to hire, develop and retain top talent. As a business, we commit to our purpose of Protecting the Vulnerable® every day by taking a customer-focused approach to developing, building, and delivering our products. We serve a broad set of industries, in particular the pharmaceutical, healthcare, and medical device industries, that require dependable quality control and calibration solutions to ensure the safety and efficacy of the products they use, and by delivering the highest quality products possible, we are committed to protecting people, the environment, and end products.

Organic Revenues Growth

Organic revenues growth is primarily driven by the expansion of our customer base, increases in sales volumes, and price increases. Our ability to increase organic revenues is affected by general economic conditions, both domestic and international, customer capital spending trends, competition, and the introduction of new products. We typically evaluate costs and pricing annually. Our policy is to price our products competitively and, where possible, we pass along cost increases to our customers in order to maintain our margins.

Page 16

Table of Contents

Inorganic Revenues Growth - Acquisitions

Over the past decade, we have consummated a number of acquisitions as part of our growth strategy. The acquisitions of these businesses, which are in addition to organic revenues growth, have allowed us to expand our product offerings, globalize our company, and increase the scale at which we operate, which in turn affords us the ability to improve our operating efficiency, extend our customer base, and further the pursuit of our purpose: Protecting the Vulnerable®. On October 20, 2021, we announced the completion of the acquisition of Agena for an aggregate purchase price of $300 million, subject to customary purchase price adjustments. Agena is a leading clinical genomics tools company that develops, manufactures, and supplies highly sensitive, low-cost, high-throughput, genetic analysis solutions to clinical labs and development partners globally. The acquisition of Agena accelerates Mesa's strategic trajectory towards higher growth applications within the regulated segments of the life sciences tools market. Going forward, we expect the substantial majority of our revenues to be generated from sales to pharmaceutical, healthcare service, and medical device verticals.

Improving Our Operating Efficiency

We maximize value in both our existing businesses and those we acquire by implementing efficiencies in our manufacturing, commercial, engineering, and administrative operations. We achieve efficiencies using the four pillars that make up The Mesa Way, which is our customer-centric, lean-based system for continuously improving and operating a set of high-margin, niche businesses. The Mesa Way is focused on: Measuring What Matters using our customers' perspective and setting high standards for performance; Empowering Teams to improve operationally and exceed customer expectations; Steadily Improving using lean-based tools designed to help us identify the root cause of opportunities and prioritize the biggest opportunities; and Always Learning so that performance continuously improves.

Hire, Develop, and Retain Top Talent

At the center of our organization are talented people who are capable of taking on new challenges using a team approach. It is our exceptionally talented workforce that works together and uses our lean-based tool set to find ways to continuously improve our products, our services, and ourselves, resulting in long-term value creation for our shareholders.

Business Update and COVID-19

During March 2020, the impact from the spread of COVID-19 was declared a global pandemic by the World Health Organization and a national public health emergency in the United States. We continue to monitor the pandemic, including the current spread of certain variants of the virus, and we have taken and will continue to take steps to identify and mitigate the adverse impact on, and risks to, our business (including but not limited to our employees, customers, vendors, manufacturing capabilities and capacity, and supply and distribution channels) posed by the spread of COVID-19 and the government responses thereto.

The COVID-19 pandemic began to impact our business late in fiscal year 2020, and its impacts affected our business in various ways throughout fiscal year 2021 and to some extent, into the first two quarters of fiscal year 2022. The pandemic and related public health recommendations and mandated precautions to mitigate the spread of COVID-19, including regulations to close or limit the operating hours of our laboratory and other customers, and to prevent non-essential personnel from going on-site to customer locations to service or market our products, have negatively affected our operations. Specifically, during fiscal year 2021 the Biopharmaceutical Development division, the Instruments division, and the Continuous Monitoring division were materially negatively impacted. While many recommendations and precautions that affected us in fiscal year 2021 have been rescinded in the United States, some regulations impacting our operations, particularly in Europe, affected our operations during the six months ended September 30, 2021, and continue to do so. Additionally, we believe that macroeconomic uncertainties that caused some of our customers to defer the purchase of our products persisted into the first quarter of fiscal year 2022, primarily affecting our Instruments division although, orders in the division have increased during fiscal year 2022 to date.

Sales of our hardware products have historically been more sensitive to general economic conditions than sales of our consumables. Even as the broad healthcare industry has begun to return to more normal operations resulting in increased sales levels in some of our divisions, outbreaks and increasing numbers of COVID-19 cases in many areas of the world have and may continue to result in the reinstatement of strict regulations, which we expect would result in lower sales levels. We believe that COVID-19 related uncertainties, restrictions, and suppressed demand may continue to negatively impact our business during fiscal year 2022. Even after the COVID-19 pandemic has subsided as a public health matter, we may experience material adverse impacts to our business as a result of its adverse impact on the global economy, in-person collaboration and sales efforts, and our customers’ changed purchasing behavior and confidence.

COVID-19 has also caused broad market phenomena such as supply chain disruptions, inflation, and wage pressure to which we are susceptible. Currently, supply chain constraints are affecting the ability of suppliers to provide components used to manufacture certain of our products. We experienced increased supply constraints for certain components used in our operations, particularly components used by the Instruments division. We continue to work with our suppliers to understand the existing and potential future impacts to our supply chain and are taking actions in an effort to mitigate such impacts, including pre-ordering components in higher quantities than usual, which has resulted in increased raw materials balances on our balance sheet as of September 30, 2021. However, during the quarter ended September 30, 2021, we were more impacted by our inability to acquire various components on a timely basis, which is discussed in more detail in our "Results of Operations" and "Risk Factors" below. We expect disruptions to our supply chain to persist for at least the next four to six fiscal quarters.

Apart from COVID-19, gross profit is affected by many factors including our product mix, manufacturing efficiencies, foreign currency rates, and price competition. Historically, as we have integrated our acquisitions and taken advantage of manufacturing efficiencies, our gross profit percentages for some products have improved. There are, however, differences in gross profit percentages between product lines, and ultimately the mix of sales will continue to impact our overall gross profit.

We completed the previously-announced closure of our Butler, New Jersey facility during the quarter ended June 30, 2021. The facility was primarily used in the production of our gas flow calibration and air sampling equipment, which is part of our Instruments division. We are continuing the integration process into our Lakewood, Colorado manufacturing facility. In addition, our Lakewood facility is currently undergoing renovations that will allow it to better accommodate the production of the gas flow calibration and air sampling equipment. Consolidating the production of these products is expected to reduce facilities costs and streamline our use of lean manufacturing tools under central management to further encourage production efficiencies.

Page 17

Table of Contents

Results of Operations

Our results of operations and period-over-period changes are discussed in the following section. The tables and discussion below should be read in conjunction with the accompanying Unaudited Condensed Consolidated Financial Statements and the notes thereto appearing in Item 1. Financial Statements (in thousands, except percent data).

Revenues from our reportable segments increased 12% and 14% for the three and six months ended September 30, 2021, respectively. The revenues growth was entirely a result of organic revenues growth. Gross profit as a percentage of revenues decreased two percentage and three percentage points for the three and six months ended September 30, 2021, respectively, compared to the three and six months ended September 30, 2020, respectively. Results by reportable segment are as follows:

|  | Revenues |  |  | Organic Revenues Growth |  |  | Gross Profit as a % of Revenues |
|  | Three Months Ended September 30, 2021 |  |  | Three Months Ended September 30, 2020 |  |  | Three Months Ended September 30, 2021 |  |  | Three Months Ended September 30, 2020 |  |  | Three Months Ended September 30, 2021 |  |  | Three Months Ended September 30, 2020 |
Sterilization and Disinfection Control |  | $ | 14,033 |  |  | $ | 11,552 |  |  |  | 21 | % |  |  | (4 | %) |  |  | 75 | % |  |  | 76 | %
Biopharmaceutical Development |  |  | 10,555 |  |  |  | 9,131 |  |  |  | 16 | % |  |  | N/A |  |  |  | 63 | % |  |  | 68 | %
Instruments |  |  | 6,970 |  |  |  | 7,558 |  |  |  | (8 | %) |  |  | (16 | %) |  |  | 59 | % |  |  | 64 | %
Continuous Monitoring |  |  | 4,282 |  |  |  | 3,619 |  |  |  | 18 | % |  |  | 1 | % |  |  | 47 | % |  |  | 38 | %
Mesa Labs' reportable segments |  | $ | 35,840 |  |  | $ | 31,860 |  |  |  | 12 | % |  |  | (8 | %) |  |  | 65 | % |  |  | 67 | %

|  | Revenues |  |  | Organic Revenues Growth |  |  | Gross Profit as a % of Revenues |
|  | Six Months Ended September 30, 2021 |  |  | Six Months Ended September 30, 2020 |  |  | Six Months Ended September 30, 2021 |  |  | Six Months Ended September 30, 2020 |  |  | Six Months Ended September 30, 2021 |  |  | Six Months Ended September 30, 2020 |
Sterilization and Disinfection Control |  | $ | 29,183 |  |  | $ | 24,619 |  |  |  | 19 | % |  |  | 2 | % |  |  | 75 | % |  |  | 76 | %
Biopharmaceutical Development |  |  | 19,432 |  |  |  | 15,080 |  |  |  | 29 | % |  |  | N/A |  |  |  | 58 | % |  |  | 71 | %
Instruments |  |  | 14,532 |  |  |  | 15,238 |  |  |  | (5 | %) |  |  | (18 | %) |  |  | 60 | % |  |  | 63 | %
Continuous Monitoring |  |  | 7,613 |  |  |  | 6,864 |  |  |  | 11 | % |  |  | (1 | %) |  |  | 46 | % |  |  | 37 | %
Mesa Labs' reportable segments |  | $ | 70,760 |  |  | $ | 61,801 |  |  |  | 14 | % |  |  | (6 | %) |  |  | 64 | % |  |  | 67 | %

Our unaudited condensed consolidated results of operations are as follows:

|  | Three Months Ended September 30, |  |  | Percentage |  |  | Six Months Ended September 30, |  |  | Percentage |
|  | 2021 |  |  | 2020 |  |  | Change |  |  | 2021 |  |  | 2020 |  |  | Change |
Revenues |  | $ | 35,840 |  |  | $ | 31,860 |  |  |  | 12 | % |  | $ | 70,760 |  |  | $ | 61,801 |  |  |  | 14 | %
Gross profit |  |  | 23,140 |  |  |  | 21,285 |  |  |  | 9 | % |  |  | 45,351 |  |  |  | 41,625 |  |  |  | 9 | %
Operating expenses |  |  | 18,939 |  |  |  | 16,815 |  |  |  | 13 | % |  |  | 38,027 |  |  |  | 33,585 |  |  |  | 13 | %
Operating income |  |  | 4,201 |  |  |  | 4,470 |  |  |  | (6 | %) |  |  | 7,324 |  |  |  | 8,040 |  |  |  | (9 | %)
Net income |  | $ | 3,720 |  |  | $ | 2,679 |  |  |  | 39 | % |  | $ | 5,715 |  |  | $ | 3,896 |  |  |  | 47 | %

Reportable Segments

Sterilization and Disinfection Control

Our Sterilization and Disinfection Control division manufactures and sells biological, cleaning, and chemical indicators. Biological, cleaning, and chemical indicators are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. The division also provides testing and laboratory services, mainly to the dental industry. Sterilization and disinfection control products are disposable and are used on a routine basis.

|  | Three Months Ended September 30, |  |  | Percentage |  |  | Six Months Ended September 30, |  |  | Percentage |
|  | 2021 |  |  | 2020 |  |  | Change |  |  | 2021 |  |  | 2020 |  |  | Change |
Revenues |  | $ | 14,033 |  |  | $ | 11,552 |  |  |  | 21 | % |  | $ | 29,183 |  |  | $ | 24,619 |  |  |  | 19 | %
Gross profit |  |  | 10,486 |  |  |  | 8,770 |  |  |  | 20 | % |  |  | 21,914 |  |  |  | 18,790 |  |  |  | 17 | %
Gross profit as a % of revenues |  |  | 75 | % |  |  | 76 | % |  |  | (1 | %) |  |  | 75 | % |  |  | 76 | % |  |  | (1 | %)

Page 18

Table of Contents

Sterilization and Disinfection Control revenues increased 21% and 19% for the three and six months ended September 30, 2021, respectively, which was achieved through effective efforts by our sales team to market and sell certain products to a larger customer base, particularly in Europe, volume increases with existing customers, and recovery of the healthcare services markets, partially offset by a modest strengthening of the U.S. dollar against the euro.

Sterilization and Disinfection Control gross profit percentage decreased one percentage point for both the three and six months ended September 30, 2021, primarily as a result of product mix and slightly higher production costs.

Biopharmaceutical Development

Our Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Immunoassays and peptide synthesis solutions accelerate the discovery, development, and manufacturing of biotherapeutic drugs.

|  | Three Months Ended September 30, |  |  | Percentage |  |  | Six Months Ended September 30, |  |  | Percentage |
|  | 2021 |  |  | 2020 |  |  | Change |  |  | 2021 |  |  | 2020 |  |  | Change |
Revenues |  | $ | 10,555 |  |  | $ | 9,131 |  |  |  | 16 | % |  | $ | 19,432 |  |  | $ | 15,080 |  |  |  | 29 | %
Gross profit |  |  | 6,601 |  |  |  | 6,212 |  |  |  | 6 | % |  |  | 11,293 |  |  |  | 10,678 |  |  |  | 6 | %
Gross profit as a % of revenues |  |  | 63 | % |  |  | 68 | % |  |  | (5 | %) |  |  | 58 | % |  |  | 71 | % |  |  | (13 | %)

Biopharmaceutical Development's revenues increased 16% and 29% for the three and six months ended September 30, 2021, respectively, due primarily increased sales of consumables as our laboratory customers were open for more normal operating hours in the first two quarters of fiscal year 2022 compared to the first two quarters of fiscal year 2021. The division's laboratory customers used significantly more consumables, driving 61% and 70% increases in consumables revenues for the three and six months ended September 30, 2021, respectively. To a lesser extent, increased digital marketing and sales efforts increased revenues in the Biopharmaceutical Development division.

Biopharmaceutical Development's gross profit percentage was 63% for the quarter ended September 30, 2021. The gross profit percentage decreased as compared to the quarter ended September 30, 2020 as a result of a slightly unfavorable change in foreign exchange rates and higher labor costs, as well as unfavorable product mix. Biopharmaceutical Development's gross profit percentage was 58% for the six months ended September 30, 2021 as a result of a significantly unfavorable change in foreign exchange rates, the benefit of a positive $258 purchase accounting adjustment in the six months ended September 30, 2020, higher labor-related costs, and unfavorable product mix.

Substantially all of this division's sales are invoiced in either euros or U.S. dollars ("USD"); however, the majority of the costs in this division are recorded in Swedish Krona and translated to USD for reporting purposes. The USD was significantly weaker against the SEK during the quarter ended June 30, 2021 compared to the quarter ended June 30, 2020, and although the USD strengthened to some extent during the quarter ended September 30, 2021, our reported costs in USD have increased substantially, while revenues have not benefited significantly from the change in currency valuation.

Instruments

Our Instruments division designs, manufactures, and markets quality control instruments and consumable products utilized in the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, and environmental air sampling industries. Instrument products have a longer life, and their purchase by our customers is discretionary, so sales are more sensitive to general economic conditions. Service demand is driven by our customers’ quality control and regulatory environments, which require periodic repair and recalibration or certification of our instrument products.

|  | Three Months Ended September 30, |  |  | Percentage |  |  | Six Months Ended September 30, |  |  | Percentage |
|  | 2021 |  |  | 2020 |  |  | Change |  |  | 2021 |  |  | 2020 |  |  | Change |
Revenues |  | $ | 6,970 |  |  | $ | 7,558 |  |  |  | (8 | %) |  | $ | 14,532 |  |  | $ | 15,238 |  |  |  | (5 | %)
Gross profit |  |  | 4,112 |  |  |  | 4,852 |  |  |  | (15 | %) |  |  | 8,772 |  |  |  | 9,541 |  |  |  | (8 | %)
Gross profit as a % of revenues |  |  | 59 | % |  |  | 64 | % |  |  | (5 | %) |  |  | 60 | % |  |  | 63 | % |  |  | (3 | %)

Instruments division revenues decreased 8% and 5% for the three and six months ended September 30, 2021, respectively, primarily as a result of supply and labor constraints, despite increased orders within the division. Particularly during the quarter ended September 30, 2021, we experienced constraints in the supply chain for components used in Instruments division products. Although fulfillment of some orders is delayed, to-date we have been able to retain the significant majority of our customers and orders. Separately, during the quarter ended June 30, 2021, order fulfillment of gas flow calibration and air sampling equipment was lower than the quarter ended June 30, 2020 as we worked to relocate the manufacturing of those items from our Butler, New Jersey facility to our Lakewood, Colorado facility, including hiring manufacturing employees to fulfill orders.

Instruments gross profit percentage decreased five percentage points and three percentage points during the three and six months ended September 30, 2021, respectively. The decrease in gross profit percentage resulted from lower revenues on a partially fixed cost base, higher labor costs as a result of a strong competition for employees in the labor market, increased costs for components and supplies, and to a lesser extent, increased freight on purchased components. Supply chain disruptions are expected to continue for at least the next four to six quarters, although these increased costs will negatively impact gross profit percentage only until we implement price increases to our customers during the fourth quarter of fiscal year 2022.

Page 19

Table of Contents

Continuous Monitoring

Our Continuous Monitoring division designs, develops, and markets systems which are used to monitor various environmental parameters such as temperature, humidity, and differential pressure to ensure that critical storage and processing conditions are maintained in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies, and laboratory environments. Continuous Monitoring products and systems have a longer life, and their purchase by our customers is discretionary, so sales are sensitive to general economic conditions. Continuous monitoring products may be sold in conjunction with a perpetual or subscription-based software license, which may be required for the related hardware to function. Service demand is driven by our customers’ quality control and regulatory environments, which require periodic repair and recalibration or certification of our continuous monitoring systems.

|  | Three Months Ended September 30, |  |  | Percentage |  |  | Six Months Ended September 30, |  |  | Percentage |
|  | 2021 |  |  | 2020 |  |  | Change |  |  | 2021 |  |  | 2020 |  |  | Change |
Revenues |  | $ | 4,282 |  |  | $ | 3,619 |  |  |  | 18 | % |  | $ | 7,613 |  |  | $ | 6,864 |  |  |  | 11 | %
Gross profit |  |  | 2,016 |  |  |  | 1,368 |  |  |  | 47 | % |  |  | 3,468 |  |  |  | 2,552 |  |  |  | 36 | %
Gross profit as a % of revenues |  |  | 47 | % |  |  | 38 | % |  |  | 9 | % |  |  | 46 | % |  |  | 37 | % |  |  | 9 | %

The Continuous Monitoring division's revenues increased 18% and 11% for the three and six months ended September 30, 2021, due primarily to an increase in customers allowing access to their facilities as our service technicians were able to go to client sites to complete service requests and hardware installations. Our ability to go on-site to many of our customers facilities to install and service systems was severely restricted during parts of the first six months of fiscal year 2021. As this division's sales are exclusively in North America, the majority of COVID-19 related restrictions that affected our ability to generate revenue in fiscal year 2021 were relaxed during the first six months of fiscal year 2022.

Continuous Monitoring gross profit percentage increased nine percentage points for both the three and six months ended September 30, 2021, primarily due to modifications made to our product offerings and pricing models which were implemented during the first quarter of fiscal year 2021, and to a lesser extent, the reorganization of the business during the first quarter of fiscal year 2021.

Operating Expenses

Operating expenses increased 13% for both the three and six months ended September 30, 2021 compared to the three and six months ended September 30, 2020 as our overall business grew.

Selling

Selling expense is driven primarily by labor costs, including salaries and commissions; accordingly, it may vary with sales levels.

|  | Three Months Ended September 30, |  |  | Percentage |  |  | Six Months Ended September 30, |  |  | Percentage |
|  | 2021 |  |  | 2020 |  |  | Change |  |  | 2021 |  |  | 2020 |  |  | Change |
Selling expense |  | $ | 4,643 |  |  | $ | 3,786 |  |  |  | 23 | % |  | $ | 9,501 |  |  | $ | 7,861 |  |  |  | 21 | %
As a percentage of revenues |  |  | 13 | % |  |  | 12 | % |  |  | 1 | % |  |  | 13 | % |  |  | 13 | % |  |  | - | %

Selling expense for the three and six months ended September 30, 2021 increased 23% and 21%, respectively, as we executed on our previously-announced plan to invest in sales and marketing resources in order to increase organic revenues growth. Specifically, we hired several sales employees during the first quarter of fiscal year 2022, resulting in higher labor-related costs, including accruing commissions on higher sales. Further, we continued to invest in new marketing materials to support our sales staff. As a percentage of revenues, selling expense was 13% for both the three and six months ended September 30, 2021, compared to 12% and 13% for the three and six months ended September 30, 2020, respectively. We expect total selling expense will approximate 13% to 16% of revenues for fiscal year 2022.

General and Administrative

Labor costs including non-cash stock-based compensation, and amortization of intangible assets drive the substantial majority of our general and administrative expense.

|  | Three Months Ended September 30, |  |  | Percentage |  |  | Six Months Ended September 30, |  |  | Percentage |
|  | 2021 |  |  | 2020 |  |  | Change |  |  | 2021 |  |  | 2020 |  |  | Change |
General and administrative expense |  | $ | 11,683 |  |  | $ | 10,615 |  |  |  | 10 | % |  | $ | 23,102 |  |  | $ | 20,714 |  |  |  | 12 | %
As a percentage of revenues |  |  | 33 | % |  |  | 33 | % |  |  | - | % |  |  | 33 | % |  |  | 34 | % |  |  | (1 | %)

General and administrative expenses increased 10% for the quarter ended September 30, 2021, as a result of increased software costs as we implemented a new human resources information and payroll system during the quarter ended September 30, 2021, and unfavorable changes in foreign exchange rates, as general and administrative costs incurred in Uppsala, Sweden are recorded in Swedish Krona and translated to USD for reporting purposes. Since the USD has weakened against the Swedish Krona during the quarter ended September 30, 2021 as compared to the quarter ended September 30, 2020, our reported costs in USD have increased.

General and administrative expenses increased 12% for the six months ended September 30, 2021, primarily as a result of higher stock-based compensation expense, increased amortization costs resulting from a $344 cumulative effect decrease to amortization expense recorded during the first quarter of fiscal year 2021 as part of a purchase price adjustment, increased software costs as we implemented a new human resources information and payroll system during the three months ended September 30, 2021, and unfavorable change in foreign exchange rates. Our stock-based compensation expense increased in the six months ended September 30, 2021 primarily because we modified an RSU that resulted in recognition of compensation costs totaling $351 during the quarter ended June 30, 2021 and we issued restricted stock units in place of a portion of our executive team's cash bonuses and salaries, which were outstanding for a larger portion of the six months ended September 30, 2021 compared to the six months ended September 30, 2020.

Page 20

Table of Contents

Research and Development

Research and development expense is predominantly comprised of labor costs and costs of third-party consultants.

|  | Three Months Ended September 30, |  |  | Percentage |  |  | Six Months Ended September 30, |  |  | Percentage |
|  | 2021 |  |  | 2020 |  |  | Change |  |  | 2021 |  |  | 2020 |  |  | Change |
Research and development expense |  | $ | 2,613 |  |  | $ | 2,414 |  |  |  | 8 | % |  | $ | 5,424 |  |  | $ | 5,010 |  |  |  | 8 | %
As a percentage of revenues |  |  | 7 | % |  |  | 8 | % |  |  | (1 | %) |  |  | 8 | % |  |  | 8 | % |  |  | - | %

Research and development expenses increased 8% for the three and six months ended September 30, 2021, primarily as a result of third-party contractor expenditures supporting our continued incremental investments in enhancing existing products as well as the development of new products and features, as well as unfavorable changes in foreign exchange rates for costs incurred in Uppsala, Sweden. We expect research and development expenses will continue to approximate 7% to 10% of revenues in the near term.

Nonoperating Expense

|  | Three Months Ended September 30, |  |  | Percentage |  |  | Six Months Ended September 30, |  |  | Percentage |
|  | 2021 |  |  | 2020 |  |  | Change |  |  | 2021 |  |  | 2020 |  |  | Change |
Nonoperating (income) expense |  | $ | (342 | ) |  |  | 2,086 |  |  |  | (116 | %) |  | $ | 1,363 |  |  | $ | 4,902 |  |  |  | (72 | %)

Nonoperating expense for the three and six months ended September 30, 2021 is composed primarily of interest expense and amortization of the debt discount associated with our 1.375% convertible senior notes due August 15, 2026 (the "Notes") and gains and losses on foreign currency transactions.

Interest expense and amortization of debt discount decreased for the three and six months ended September 30, 2021 compared to the three and six months ended September 30, 2020 due to our adoption of ASU 2020-06, which resulted in a reduction in non-cash interest expense related to the Notes. Nonoperating expenses also decreased as we recorded net unrealized gains on foreign currency related to certain of our intercompany notes resulting from the movement of the Swedish Krona against the USD.

Income Taxes

|  | Three Months Ended September 30, |  |  | Percentage |  |  | Six Months Ended September 30, |  |  | Percentage |
|  | 2021 |  |  | 2020 |  |  | Change |  |  | 2021 |  |  | 2020 |  |  | Change |
Income tax provision (benefit) |  | $ | 823 |  |  | $ | (295 | ) |  |  | (379 | %) |  | $ | 246 |  |  | $ | (758 | ) |  |  | (132 | %)
Effective tax rate |  |  | 18 | % |  |  | (12 | %) |  |  | 30 | % |  |  | 4 | % |  |  | (24 | %) |  |  | 28 | %

Our effective tax rate benefited notably from the the exercise of stock options and to a lesser extent, the benefit of federal derived intangible income, partially offset by the limitations imposed by Section 162(m) and higher state income taxes. Our income tax rate varies based upon many factors, but in general, we anticipate that on a go-forward basis our effective tax rate will be approximately 26%, plus or minus the impact of excess tax benefits and deficiencies associated with share-based payment awards to employees; see Note 9. “Income Taxes” within Item 1. Financial Statements for additional discussion. The excess tax benefits and deficiencies associated with share-based payment awards to our employees have caused and, in the future, may cause large fluctuations in our realized effective tax rate based on timing, volume, and nature of stock options exercised under our share-based payment program.

Net Income

Net income for the six months September 30, 2021 varied with the changes in revenues, gross profit, and operating expenses (and includes $7,573 and $4,236 of non-cash amortization of intangible assets acquired in a business combination, and stock-based compensation, respectively). Prior to the adoption of ASU 2020-06 on April 1, 2021, we were required to recognize non-cash interest expense related to the amortization of debt discounts and issuance costs. Subsequent to the adoption, we recognize non-cash interest expense related to amortization of debt issuance costs only, resulting in higher net income subsequent to the adoption of ASU 2020-06.

Liquidity and Capital Resources

Our sources of liquidity include cash generated from operations, cash and cash equivalents on hand, working capital and potential additional equity and debt offerings. Despite lingering uncertainties surrounding the economic impacts of the COVID-19 pandemic, we continue to believe that we have the liquidity required to continue operations even if volatility in the economic environment reoccurs. We believe that cash and cash equivalents on hand and cash generated from operations, as well as the reminder of the unused capacity under our Credit Facility will be sufficient to meet our short-term and long-term needs.

Our more significant uses of resources have historically included acquisitions, long-term capital expenditures, payment of debt and interest obligations, and quarterly dividends to shareholders. Working capital is the amount by which current assets exceed current liabilities. We had working capital of $290,714 and $271,166 as of September 30, 2021, and March 31, 2021, respectively. As of September 30, 2021, and March 31, 2021, we had $278,294 and $263,865, respectively, of cash and cash equivalents, which were held primarily in money market funds. We consider all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.

Page 21

Table of Contents

During fiscal year 2021, we entered into a four-year senior secured credit agreement that includes 1) a revolving credit facility in an aggregate principal amount of up to $75,000, 2) a swingline loan in an aggregate principal amount not exceeding $5,000, and 3) letters of credit in an aggregate stated amount not exceeding $2,500 at any time. The Credit Facility also provides for an incremental term loan or an increase in revolving commitments in an aggregate principal amount of at a minimum $25,000 and at a maximum $75,000, subject to the satisfaction of certain conditions and lender considerations. As of September 30, 2021, we had not drawn from the Credit Facility.

On October 20, 2021, we completed the acquisition of Agena for $300,000, subject to customary purchase price adjustments, pursuant to the terms of the previously announced Agreement and Plan of Merger dated September 13, 2021. We funded the acquisition and transactions relating thereto with cash on hand, and on October 18, 2021, we drew $70,000 on our existing line of credit for cash funds necessary to complete the acquisition. Following the draw, we had $5,000 remaining available to draw on the line of credit.

As of September 30, 2021, $172,500 in aggregate principal amount Notes was outstanding. The Notes bear interest at a rate of 1.375% payable semi-annually in arrears on February 15 and August 15 of each year, beginning with our first payment made on February 15, 2020. These Notes can be converted by holders prior to maturity if certain conditions are met. We currently expect to settle future conversions of the Notes entirely in shares of our common stock and will reevaluate this policy from time to time in the event that conversion conditions are met and conversion notices are received from holders of the Notes. We were in compliance with all debt agreements at September 30, 2021 and for all prior years presented and have met all debt payment obligations. Refer to Note 6. "Indebtedness" within Item 1. Financial Statements for more details on these transactions.

We routinely evaluate opportunities for strategic acquisitions. Future material acquisitions may require that we obtain additional capital, assume additional third-party debt or incur other long-term obligations. We believe that we have the ability to issue more equity or debt in the future in order to finance our acquisition and investment activities, however, additional equity or debt financing, or other transactions, may not be available on acceptable terms, if at all.

We may from time to time repurchase or otherwise retire our debt and take other steps to reduce our debt. These actions may include retirements or refinancing of outstanding debt, privately negotiated transactions or otherwise. The amount of debt that may be retired, if any, could be material and would be decided at the sole discretion of our Board of Directors and will depend on market conditions, our cash position and other considerations.

Dividends

We have paid regular quarterly dividends since 2003. We declared and paid dividends of $0.16 per share during each of the quarters ended June 30, 2021 and September 30, 2021, as well as each quarter of fiscal year 2021.

In October 2021, we announced that our Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, payable on December 15, 2021, to shareholders of record at the close of business on November 30, 2021.

Cash Flows

Our cash flows from operating, investing, and financing activities were as follows (in thousands):

|  | Six Months Ended September 30, |
|  | 2021 |  |  | 2020 |
Net cash provided by operating activities |  | $ | 14,023 |  |  | $ | 12,610 |
Net cash (used in) investing activities |  |  | (1,591 | ) |  |  | (707 | )
Net cash provided by financing activities |  |  | 1,423 |  |  |  | 147,104 |

Cash flows from operating activities for the six months ended September 30, 2021 provided $14,023. The $1,413 increase in cash flows from operations primarily resulted from increased net income and and increased non-cash stock-based compensation expense, partially offset by lower depreciation and amortization and lower non cash interest expense as a result of the adoption of ASU 2020-06. Further, cash used by operating assets and liabilities decreased by $887 for the six months ended September 30, 2021 compared to the six months ended September 30, 2020. Cash used in investing was higher during the six months ended September 30, 2021 compared to the six months ended September 30, 2020, due to purchases of property, plant, and equipment, primarily to support the renovations of our Lakewood, Colorado facility. Our equity raise completed during the quarter ended June 30, 2020 provided $145,935.

Page 22

Table of Contents

Contractual Obligations and Other Commercial Commitments

We are party to many contractual obligations that involve commitments to make payments to third parties in the ordinary course of business. For a description of our contractual obligations and other commercial commitments as of March 31, 2021, see our Form 10-K for the fiscal year ended March 31, 2021, filed with the Securities and Exchange Commission on June 1, 2021. During the three and six months ended September 30, 2021, there were no material changes with respect to the nature of our contractual obligations and other commercial commitments outside the ordinary course of business. At September 30, 2021, we had contractual obligations for open purchase orders of approximately $11,099 for routine purchases of supplies and inventory, which are payable in less than one year. Open purchase orders increased during the three months ended September 30, 2021 as we took proactive steps to mitigate risks in our supply by increasing our orders of certain critical raw materials.

Off-Balance Sheet Arrangements

As of September 30, 2021, we had no off-balance sheet arrangements or obligations.

Critical Accounting Policies and Estimates

Critical accounting estimates are those that we believe are both significant and require us to make difficult, subjective, or complex judgments, often because we need to estimate the effect of inherently uncertain matters. These estimates are based on historical experience and various other factors that we believe to be appropriate under the circumstance. Actual amounts and results could differ from these estimates made by management. Certain accounting policies that require significant management estimates and are deemed critical to our results of operations or financial position are discussed in our Annual Report on Form 10-K for the year ended March 31, 2021, in the Critical Accounting Policies and Estimates section of Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We have no derivative instruments and minimal exposure to commodity market risks. Our reporting currency is U.S. dollars, and the functional currency of each of our foreign subsidiaries is its respective local currency. Our operations include activities outside of the U.S. and we have currency risk on the transactions in other currencies and translation adjustments resulting from the conversion of our international financial results into the U.S. dollar. We face currency exposures in our global operations as a result of various factors including intercompany currency denominated loans, selling our products in various currencies, purchasing raw materials and equipment in various currencies and tax exposures not denominated in the functional currency. These exposures have increased as we have continued to expand internationally, including the acquisition of GPT, which conducts a substantial portion of its business expenses in Swedish Krona. Fluctuations in exchange rates have, and may continue to adversely affect our results of operations, financial position, and cash flows; however we do not believe a 10% adverse change in currency would materially affect our consolidated results.

We hold investments in money market funds. As a result, we are exposed to potential loss from market risks that may occur as a result of changes in interest rates, credit quality of the issuer, or other factors.

Item 4. Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are designed to ensure that information required to be disclosed in Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Evaluation of Disclosure Controls and Procedures

As of September 30, 2021, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

Changes in Internal Control over Financial Reporting

During the three months ended September 30, 2021, we implemented a new human resources information and payroll system, which is considered to be a key system as part of our internal controls over financial reporting. We continued to integrate the software with our processes, systems, and controls in the quarter ended September 30, 2021. There were no other changes during the quarter ended September 30, 2021 in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

Page 23

Table of Contents

Part II. Other Information

Item 1. Legal Proceedings

See Note 10. “Commitments and Contingencies” within Item 1. Financial Statements for information regarding any legal proceedings in which we may be involved.

Item 1A. Risk factors

We are dependent on our suppliers to deliver components, and a shortage of key components have and could continue to disrupt our production and delay order fulfillment.

Products sold by our Instruments division, and to a lesser extent, our Biopharmaceutical Development, and Continuous Monitoring divisions contain components, including electronic components, glass, plastics, and packaging that we source globally from suppliers who, in turn, source components from their suppliers. If there is a shortage of a key component in our supply chain, and the component cannot be easily sourced from a different supplier, the shortage may disrupt our production which may, in turn, delay order fulfillment. We are experiencing long lead times, and in some cases, difficulty obtaining components from our existing suppliers, which has resulted in delayed order fulfillment in our Instruments division. In addition, costs for components, and freight for components has increased, which may reduce our gross profit margins until we are able to pass the cost increases along to our customers. There are several reasons for the supply chain disruptions to components that we rely on to manufacture our products including: increased demand for other products that use the same components as those we purchase, manufacturing shut-downs during the past 18 months that reduced production of components, labor issues, and long lead times for raw materials used in the production of components. A continued shortage of components or other key materials that comprise the components could cause a significant disruption to our production schedule and have a substantial adverse effect on our financial condition or results of operations.

Additional risks related to our supply chain include those in our FY21 Form10-K risk factors, “We face numerous manufacturing and supply chain risks. In addition, our reliance upon sole or limited sources of supply for certain materials, components and services could cause production interruptions, delays and inefficiencies.”

During the quarter there were no other material changes from the risk factors described in Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended March 31, 2021.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On November 7, 2005, our Board of Directors adopted a share repurchase plan which allows for the repurchase of up to 300,000 of our common shares, of which 162,486 have been purchased to date; however, no shares have been purchased under the plan in the last three fiscal years. This plan will continue until the maximum is reached or the plan is terminated by further action of the Board of Directors.

Page 24

Table of Contents

Item 6. Exhibits

Exhibit No. | Description of Exhibit
10.2.3 | Mesa Laboratories, Inc. 2021 Equity Incentive Plan (incorporated by reference from exhibit 10.2.3 to Mesa Laboratories, Inc.'s Form S-8 filed on August 30, 2021 (Commission File Number: 333-259154)
10.3.7 | Form of 2021 Equity Incentive Plan Option Award Agreement (incorporated by reference from exhibit 10.3.7 to Mesa Laboratories, Inc.'s Form S-8 filed on August 30, 2021 (Commission File Number: 333-259154)
10.3.8 | Form of 2021 Equity Incentive Plan Restricted Stock Unit Agreement (incorporated by reference from exhibit 10.3.8 to Mesa Laboratories, Inc.'s Form S-8 filed on August 30, 2021 (Commission File Number: 333-259154)
31.1+ | Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2+ | Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1* | Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2* | Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS+ | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH+ | Inline XBRL Taxonomy Extension Schema Document.
101.CAL+ | Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF+ | Inline XBRL Taxonomy Extension Definitions Linkbase Document
101.LAB+ | Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE+ | Inline XBRL Taxonomy Extension Presentation Linkbase Document
104+ | Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*).

+ Filed herewith

* Furnished herewith

Page 25

Table of Contents

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MESA LABORATORIES, INC.

(Registrant)

DATED: November 4, 2021 | BY: | /s/ Gary M. Owens. Gary M. Owens Chief Executive Officer
DATED: November 4, 2021 | BY: | /s/ John V. Sakys John V. Sakys Chief Financial Officer

Page 26